

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19:

Serologic Testing

Authors: Mary K. Hayden¹, Ibrahim K. El Mikati^{2,3}, Kimberly E. Hanson⁴, Janet A. Englund⁵,
Romney M. Humphries⁶, Francesca Lee⁷, Mark Loeb⁸, Daniel J. Morgan⁹, Robin Patel¹⁰, Omar Al
Ta'ani¹¹, Jamil Nazzal¹², Shahad Iqneibi¹³, Justin Z. Amarín¹⁴, Shahnaz Sultan¹⁵, Yngve Falck-
Ytter¹⁶, Rebecca L. Morgan¹⁷, M. Hassan Murad¹⁸, Adarsh Bhimraj¹⁹, Reem A. Mustafa²⁰

Affiliations:

¹Division of Infectious Diseases, Department of Medicine, Rush University Medical Center,
Chicago, Illinois; Department of Pathology, Rush University Medical Center, Chicago, Illinois

²Outcomes and Implementation Research Unit, Department of Internal Medicine, University of
Kansas Medical Center, Kansas City, Kansas

³Department of Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland

⁴Divisions of Infectious Diseases and Clinical Microbiology, University of Utah, Salt Lake City,
Utah

⁵Department of Pediatrics, University of Washington, Seattle Children's Research Institute,
Seattle, Washington

⁶Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville,
Tennessee

⁷Departments of Pathology and Internal Medicine, University of Texas Southwestern Medical
Center, Dallas, Texas

⁸Division of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

⁹Department of Epidemiology and Public Health, University of Maryland School of Medicine,
Baltimore, Maryland

¹⁰Division of Clinical Microbiology, Division of Public Health, Infectious Diseases, and
Occupational Medicine, Mayo Clinic, Rochester, Minnesota

¹¹ Department of Internal Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania

¹² Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan

¹³Faculty of Medicine, University of Jordan, Amman, Jordan

¹⁴Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville,
Tennessee

¹⁵Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota,
Minneapolis VA Healthcare System, Minneapolis, Minnesota

¹⁶Department of Medicine, Case Western Reserve University, School of Medicine, Cleveland,
Ohio

¹⁷Department of Health Research Methods, Evidence and Impact, McMaster University,
Hamilton, Ontario

¹⁸Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic,
Rochester, Minnesota

¹⁹Houston Methodist, Director, Infectious Diseases Fellowship and Education, Division of
Infectious Diseases, Houston Methodist Hospital, Center of Excellence for Infectious Diseases
Houston Methodist Research Institute, Houston, Texas

²⁰Division of Nephrology and Hypertension, Department of Internal Medicine, University of
Kansas Medical Center, Kansas City, Kansas

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

46 **Corresponding Author:** Mary K. Hayden

47

48 **Panel Members:** Mary K. Hayden (lead), Kimberly E. Hanson, Janet A. Englund (PIDS
49 representative), Romney M. Humphries, Francesca Lee, Mark Loeb (SHEA representative),
50 Daniel J. Morgan, Robin Patel (ASM representative), Adarsh Bhimraj

51

52 **Methodologists:** Reem A. Mustafa (lead), Ibrahim K. El Mikati, Omar Al Ta'ani, Jamil Nazzal,
53 Shahad Iqneibi, Justin Z. Amarin, Shahnaz Sultan, Yngve Falck-Ytter, Rebecca L. Morgan, M.
54 Hassan Murad

55

Abstract

Background: The role of serologic testing for SARS-CoV-2 has evolved during the pandemic as seroprevalence in global populations has increased. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the coronavirus disease 2019 (COVID-19) serology literature and construct updated best practice guidance related to SARS-CoV-2 serologic testing. This guideline is an update to the fourth in a series of rapid, frequently updated COVID-19 guidelines developed by IDSA.

Objective: To develop evidence-based recommendations and identify unmet research needs pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, decisions related to vaccination and administration of monoclonal antibodies or convalescent plasma in immunocompromised patients, and identification of a serologic correlate of immunity.

Methods: A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists and experts in systematic literature reviewed, identified, and prioritized clinical questions related to the use of SARS-CoV-2 serologic tests. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations.

Results: The panel recommends against serologic testing to diagnose SARS-CoV-2 infection in the first two weeks after symptom onset (strong recommendations, low certainty of evidence).

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

Serologic testing should not be used to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative nucleic acid amplification test results (strong recommendation, very low certainty of evidence). Serologic testing may assist with the diagnosis of multisystem inflammatory syndrome in children (strong recommendation, very low certainty of evidence). To seek evidence for prior SARS-CoV-2 infection, the panel suggests testing for IgG, IgG/IgM, or total antibodies to nucleocapsid protein three to five weeks after symptom onset (conditional recommendation, low certainty of evidence). In individuals with previous SARS-CoV-2 infection or vaccination, we suggest against routine serologic testing given no demonstrated benefit to improving patient outcomes (conditional recommendation, very low certainty of evidence.) The panel acknowledges further that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy.

Conclusions: The high seroprevalence of antibodies against SARS-CoV-2 worldwide limits the utility of detecting anti-SARS CoV-2 antibody. The certainty of available evidence supporting the use of serology for diagnosis was graded as very low to low. Future studies should use serologic assays calibrated to a common reference standard.

IDSA Legal Disclaimer

It is important to realize that guidelines cannot account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

voluntary, with the ultimate determination regarding their application to be made by the physician in the light of a patient's individual circumstances. While IDSA makes every effort to present accurate and reliable information, the information provided in these guidelines is "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. Neither IDSA nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with implementation of these guidelines or reliance on the information presented.

The guidelines represent the proprietary and copyrighted property of IDSA. Copyright 2024 Infectious Diseases Society of America. All rights reserved. No part of these guidelines may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of IDSA. Permission is granted to physicians and health care providers solely to copy and use the guidelines in their professional practices and clinical decision-making. No license or permission is granted to any person or entity, and prior written authorization by IDSA is required, to sell, distribute, or modify the guidelines, or to make derivative works of or incorporate the guidelines into any product, including but not limited to clinical decision support software or any other software product. Except for the permission granted above, any person or entity desiring to use the guidelines in any way must contact IDSA for approval in accordance with the terms and conditions of third-party use, in particular any use of the guidelines in any software product.

Executive Summary

As of December 2022, more than 96% of the U.S. population was estimated to have antibodies against SARS-CoV-2 [1]. While global seroprevalence data are more sparse, similar estimates have been reported from numerous other countries and regions [2]. The utility of anti-SARS-CoV-2 antibody testing for diagnostic or epidemiologic purposes has declined as global seroprevalence due to vaccination and natural infection has increased. The current IDSA Guideline for Serologic Testing in the Diagnosis of SARS-COV-2 Infection reflects this evolution. The panel now makes a strong (versus weak) recommendation against serologic testing to diagnose acute COVID-19 in the first 2 weeks after symptom onset. Similarly, the updated guideline recommends strongly against (versus previously recommending weakly for) using IgG antibodies to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative nucleic acid amplification tests (NAAT). Unlike NAAT which detect viral RNA, antibody-based assays measure the host's humoral immune response to current or past infection. Anti-SARS-CoV-2 antibodies typically become detectable more than two weeks after onset of symptoms ([Figure 1](#)). As a result, SARS-CoV-2 serology lacks sufficient sensitivity to confidently exclude a diagnosis of coronavirus disease 2019 (COVID-19) when antibodies are not detected in the acute phase of illness. Furthermore, given the very high baseline seroprevalence of anti-SARS-CoV-2 antibodies in most populations, a positive serologic result may likely be due to vaccination or a distant history of COVID-19 as opposed to an acute or recent SARS-CoV-2 infection.

For the current update, the panel identified very few clinical scenarios in which serologic testing may be useful. The first to assist in the diagnosis of Multisystem Inflammatory


Syndrome in children (MIS-C). In addition, the panel agreed that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy, such as convalescent plasma or monoclonal antibodies, if such therapy were available, or to prioritize administration of monoclonal therapies when supplies are limited. When antibody testing is done, the panel makes a weak recommendation for using SARS-CoV-2 IgG, IgG/IgM, or total antibodies and against using IgM, due to lower sensitivity of IgM alone. IgA tests were not considered in the current, updated guideline because of their past poor performance and because they are rarely tested in clinical laboratories.

The current IDSA guideline includes two new recommendations. The first is a weak recommendation to use serologic assays that target nucleocapsid protein rather than spike protein when evidence of prior COVID-19 is desired. This recommendation is made to improve the specificity of testing in highly vaccinated populations, since most available vaccines result in formation of anti-spike antibodies, although some inactivated whole virus vaccines (e.g., CoronaVac and BBIBP-CorV, manufactured by Sinovac and Sinopharm, respectively) can also result in formation of anti-nucleocapsid antibodies.

The second new recommendation suggests against routine serologic testing in patients with previous SARS-CoV-2 infection or vaccination, given that no demonstrated benefits for improving patient outcomes were identified. Data were found to support higher levels of binding antibodies or the presence of neutralizing antibodies as being associated with protection against SARS-CoV-2 infection, but a single titer that predicts protection was not identified.

Summarized below are specific recommendations and comments related to the use of SARS-CoV-2 serologic testing in clinical practice. A detailed description of background, methods, evidence summary and rationales that support each recommendation can be found online and in the full text.

Figure 1. Detection of SARS-CoV-2 antibodies after symptom onset in patients with COVID-19. Panel a: Sensitivity of detection of anti-nucleocapsid (N) and anti-spike (S) antibodies over time, stratified by antibody class. Panel b: Sensitivity of assays that detect SARS-CoV-2 IgG, IgM, IgM/IgG, and total antibody over time, stratified by antibody target.



171 **Recommendation 1:** The IDSA panel recommends against using serologic testing to diagnose
172 SARS-CoV-2 infection during the first two weeks following symptom onset (strong
173 recommendation, low certainty of evidence).

174 **Remarks:**

- 175 • Most studies included in this recommendation's literature review assessed
176 unvaccinated individuals and so the panel's findings might not apply to
177 individuals who have been vaccinated, especially with respect to specificity,
178 rendering test accuracy worse than presented here.
- 179 • Similarly, in today's population there is a higher likelihood of prior SARS-CoV-2
180 infection than assessed in the included studies, which could also negatively
181 affect specificity, rendering test accuracy worse than presented.
- 182 • Analogous to other respiratory viruses where non-serologic tests are preferred
183 for diagnosis of acute infection, serologic testing should not be routinely
184 performed for diagnosis of acute COVID-19.

185 **Recommendation 2:** The IDSA panel recommends against using IgG antibodies to provide
186 evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly
187 negative NAAT (strong recommendation, very low certainty of evidence).

188 **Remarks**

- 189 • Contemporary populations are more likely to have had prior SARS-CoV-2
190 infection or vaccination than the populations assessed in the included studies,

which could negatively affect pooled specificity calculations, rendering test accuracy worse than presented here.

Recommendation 3: To assist with the diagnosis of multisystem inflammatory syndrome in children (MIS-C), the IDSA panel recommends using both IgG antibody testing and NAAT to provide evidence of current or recent past COVID-19 (strong recommendation, very low certainty of evidence).

Remarks:

- Combining IgG antibody testing and NAAT may improve both the ability to diagnose MIS-C and to rule it out, compared to using NAAT alone. Knowing the patient's vaccination and COVID-19 history may be helpful in interpreting serology results.
- Differentiating MIS-C from conditions with overlapping symptomatology, such as Kawasaki disease, is important because Kawasaki disease requires treatment with specific therapies such as intravenous immunoglobulin or rituximab if diagnosed. The two diseases also differ in terms of potential complications and need for long-term medication and follow-up.
- The January 2023 definition of MIS-C agreed upon by U.S. Centers for Disease Control and Prevention (CDC) and other public health officials requires evidence of current or recent SARS-CoV-2 infection by PCR, antigen, or serologic testing [3].

Recommendation 4: When evidence of previous SARS-CoV-2 infection is desired, the IDSA panel suggests testing for SARS-CoV-2 IgG, IgG/IgM, or total antibodies three to five weeks after

213 symptom onset and against testing for SARS-CoV-2 IgM (conditional recommendation, low
214 certainty of evidence).

215 **Remarks:**

- 216 • SARS-CoV-2 NAAT and antigen tests have superior performance characteristics
217 for diagnosis of COVID-19, compared to serologic testing.
- 218 • There are very limited situations in which SARS-CoV-2 antibody testing might be
219 useful, e.g., in helping to diagnose MIS-C.

220 **Recommendation 5:**

- 221 • When evidence of prior SARS-CoV-2 infection is desired, the IDSA panel suggests
222 using serologic assays that target nucleocapsid protein rather than spike protein
223 (conditional recommendation, low certainty of evidence).

224 **Remarks:**

- 225 • Most available vaccines result in formation of only anti-spike antibodies but
226 some (e.g., CoronaVac and BBIBP-CorV, manufactured by Sinovac and
227 Sinopharm, respectively) which contain inactivated whole virus, can also result in
228 formation of anti-nucleocapsid antibodies [4].
- 229 • Given the high prevalence of vaccination in most populations and the
230 persistence of anti-spike antibodies over time, detection of anti-spike antibodies
231 has low positive predictive value for diagnosis of recent COVID-19 in most
232 individuals.

233 **Recommendation 6:**

- 234 • In individuals with previous SARS-CoV-2 infection or vaccination, the IDSA panel
235 suggests against routine serologic testing given no demonstrated benefit to
236 improving patient outcomes (conditional recommendation, very low certainty of
237 evidence).

238 **Remarks**

- 239 • Serologic testing may be useful for diagnosing MIS-C in pediatric patients,
240 especially when NAAT or antigen testing is negative, to provide evidence of
241 recent COVID-19 (see Recommendation 3 above).
- 242 • A negative spike antibody test may be a useful metric to identify
243 immunocompromised patients who are candidates for immune therapy such as
244 convalescent plasma or monoclonal antibodies, if such therapies were available,
245 or to prioritize administration of monoclonal therapies when supplies are
246 limited.

247

248

Background

Since its emergence in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 760 million confirmed infections and nearly 7 million deaths worldwide [5]. Definitive diagnosis of coronavirus disease 19 (COVID-19) and asymptomatic SARS-CoV-2 infection rely on the direct detection of virus-specific RNA or virus-specific glycoprotein antigens in respiratory specimens. Serologic tests that use blood samples to detect the host antibody response to SARS-CoV-2 cannot diagnose SARS-CoV-2 infection or COVID-19, nor can they identify persons who are protected from future infection, but they may help confirm past infection. The current high seroprevalence of anti-SARS-CoV-2 antibodies in most populations limits the utility of antibody testing for clinical or epidemiologic purposes.

Coronavirus genomes encode four major structural proteins including spike (S), envelope (E), membrane (M) and nucleocapsid (N). Both the S and N proteins of SARS-CoV-2 are immunogenic in humans; current serologic tests target antibodies directed against these antigens [6]. The S protein is the most exposed viral protein and is responsible for viral attachment and entry into host cells via binding to the angiotensin-converting enzyme 2 (ACE-2) receptor [7]. The S protein is comprised of an N-terminal S1 subunit, involved in virus-receptor binding, and a C-terminal S2 subunit involved in fusion to the host cell membrane. The S1 subunit is further divided into an N terminal domain (NTD) and a receptor binding domain (RBD). There has been particular focus on the SARS-CoV-2 RBD for vaccine development and targeted antibody therapies because neutralizing antibodies against this region effectively block

viral entry [8, 9]. The N protein is an RNA-binding protein that is abundantly expressed during infection and plays a role in RNA transcription and replication [10].

There are two general types of antibodies, neutralizing antibodies (nAbs) and non-neutralizing (also known as binding antibodies) [11]. Neutralization is defined as the loss of infectivity that occurs when a nAb binds to a viral particle. Virus-specific or vaccine-induced nAbs can play a role in controlling viral infection, but definitive data is lacking to know whether individuals with detectable anti-SARS-CoV-2 nAbs are protected against reinfection. In comparison, binding antibodies are characterized by their inability to prevent viral infection of permissive cells. Regardless of their function, both types of virus-specific antibodies are potentially useful as diagnostic indicators of past infection or vaccination.

Commercially available anti-SARS-CoV-2 antibody tests use different technologies to qualitatively measure single immunoglobulin classes (IgM, IgG or IgA) or total antibody, and to differentiate nAbs from binding antibodies. IgM antibodies directed against microorganisms are typically produced first after infection and are used as a measure of recent infection. IgG antibodies generally develop later than IgM antibodies and remain elevated for months to years after infection. Although IgM antibodies can be detected within the first two weeks of symptoms in some patients, SARS-CoV-2 infection appears unusual in that IgM and IgG more commonly rise together, more than two weeks after the onset of symptoms [12]. Secretory IgA is important for mucosal immunity. IgA can also be detected systemically in certain types of infection including SARS-CoV-2, but comparatively little is known about the kinetics of IgA in blood. The components of “total antibody” presumably include IgM and IgG and theoretically other antigen-specific immunoglobulins as well.

The most common clinical diagnostic platforms utilized for SARS-CoV-2 include lateral flow (LF) devices, enzyme linked immunosorbent assays (ELISA) and chemiluminescent immunoassays (CIA). Lateral flow assays typically require a drop of blood (or serum or plasma) applied to a test strip, with results read in approximately 15-30 minutes. These devices are suitable for point-of-care testing and have potential to be deployed in the field as a part of large serological surveys. ELISA comes in a variety of different formats. Typically, a bound antigen-antibody complex is detected using a type-specific secondary antibody linked to a substrate that generates a colorimetric or fluorescent signal. CIA methods are similar to ELISA but use chemical probes that emit light instead of enzymatic substrates. Both ELISA and CIA are clinical laboratory-based methods amenable to high throughput testing using serum, plasma, or potentially dried blood spots. At this time, neutralization assays are mainly used in research settings or offered as laboratory developed tests by reference laboratories.

As of this writing, most commercially available SARS-CoV-2 antibody tests marketed in the U.S. have Emergency Use Authorization (EUA) through the U.S. Food and Drug Administration (FDA). Early in the pandemic, however, official EUA review was voluntary. Test developers were expected only to internally validate their tests and notify the FDA of their intent to market. As a result, the market was flooded with poorly performing assays. In response the FDA subsequently issued a “removed” test list that includes tests with significant performance problems, assays for which official EUA review was not appropriately submitted or assays voluntarily withdrawn by the developer. Subsequently, on September 23, 2021, the FDA revised the EUAs of certain molecular, antigen, and serology tests to establish additional Conditions of Authorization in response to the ongoing emergence of new SARS-CoV-2 variants.

The lifting of the Federal COVID-19 Public Health Emergency on May 11, 2023 was accompanied by release of a transition plan by the FDA with recommendations for marketing submission and other actions needed to enable ongoing use of COVID-19 laboratory tests that were issued EUA [13].

Many serologic tests for SARS-CoV-2 are commercially available. While most of these assays are currently available under FDA EUA, it is expected that many will soon achieve FDA clearance. The speed of development has continued to outpace rigorous assessments of test performance. In response, IDSA convened an expert panel to systematically review the available serologic literature, compare pooled estimates of test accuracy and make evidence-based recommendations for informed use in clinical practice.

Methods

This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for evidence assessment. This guideline serves as the second update to the original IDSA guidelines on the serologic testing of COVID-19 [14]. The list of questions addressed in the initial guideline and the current update can be found in Table s1.

Panel Composition

The panel was composed of clinicians and clinical microbiologists who are members of the IDSA, the American Society for Microbiology (ASM), the Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS). They

represented the disciplines of infectious diseases, pediatrics, clinical microbiology, and healthcare epidemiology. The Evidence Foundation provided technical support and guideline methodologists for the development of this guideline.

Disclosure and Management of Potential Conflicts of Interest

The conflict of interest (COI) review group included two representatives from IDSA who were responsible for reviewing, evaluating and approving all disclosures. All members of the expert panel complied with the COI process for reviewing and managing conflicts of interest, which required disclosure of any financial, intellectual, or other interest that might be construed as constituting an actual, potential, or apparent conflict, regardless of relevancy to the guideline topic. The assessment of disclosed relationships for possible COI was based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The COI review group ensured that the majority of the panel and chair were without potential relevant (related to the topic) conflicts. The chair and all members of the technical team were determined to have no COIs relevant to the guidelines.

Question Generation

Clinical questions were developed into a PICO format (Population, Intervention, Comparison, Outcomes) [15] prior to the first panel meeting. Using online surveys, the panel members decided to reassess the evidence and the recommendation for 4 PICO questions that

were addressed in the initial guideline in 2020 [14]. Additionally, panel members prioritized 3 new questions that have emerged as clinically important (Table s1). Because very limited data were identified to answer two of these questions, they were combined in a single recommendation (Recommendation 6.)

Search Strategy

The National Institute of Health and Care Excellence (NICE) and the Centers for Disease Control and Prevention (CDC) highly sensitive search was reviewed by the methodologists in consultation with an experienced information specialist and was determined to have high sensitivity. Terms identified in the PICO questions and the term “COVID” were added to the search strategy used for the databases PubMed, Embase, and Cochrane for antigen, molecular, and serology diagnostic test terms (Table s2). Monthly searches were performed from 2019 through January 1, 2023. During September 2022, with the help of an information specialist, improvements to the search strategy were made to reflect the covid19/sarscov2 epidemic and remove general terms like “coronavirus” which may pick up articles that are about a different virus. (Table s2). Any reference lists and literature suggested by the panelists were also reviewed throughout the guideline development process.

Screening and Study Selection

A member of the review team screened the titles and abstracts of the references identified by the search strategy and assessed if the study addressed antigen, molecular, or serologic testing. A member of the review team then assessed the studies addressing serologic

testing in more detail using the full texts of the studies under consideration for potential inclusion in the review. When the inclusion of an article was debated, it was first resolved through discussion within the review team. In the case of disagreement, articles were discussed with the panel members to make the final decision.

Studies were included if they reported data on the diagnostic test accuracy of anti-SARS-CoV-2 IgM, IgG, and/or total antibody tests compared to NAAT as the reference standard. Studies were excluded if the tests evaluated were not EUA or European Commission (CE) approved, studies with fewer than 30 patients/samples, studies with incomplete test accuracy information (i.e., reported sensitivity without specificity), studies reporting atypical serology sample site collection (e.g., dried blood spots, mucosal fluids), machine learning studies, protocols, preprints, and abstracts.

Data Collection and Analysis

A member of the review team completed data extraction using a standardized data extraction form. in duplicate. Study characteristics (authors, publication year, country, study design, inclusion criteria, age, gender), index test information (timing from onset of symptoms, sample type, target antigen, platform, immunoglobulin class, FDA EUA status, and European Economic Area CE marking status), reference test (name of test, sample type), and diagnostic test accuracy results (true and false positives and negatives) were extracted.

For each study, the sensitivity and specificity of the diagnostic index test were calculated and the Clopper–Pearson method used to estimate 95% confidence intervals. We then fit the random-effects bivariate binomial model of Chu and Cole [16] to pool accuracy estimates using

the glmer function of the lme4 package in R (version 4.1.2). To pool accuracy estimates for analyses including fewer than 5 studies, we fit a fixed effects model as implemented in the meta package in R (version 4.1.2). Forest plots were used to plot individual and summary estimates and conducted subgroup analyses to explore heterogeneity. To evaluate the effects of study design on results, sensitivity analyses were performed by including or excluding case control studies and assessing the effect on pooled results of test accuracy.

Risk of Bias and Certainty of Evidence

The Quality Assessment of Diagnostic Studies (QUADAS)-2 revised tool was used to assess the risk of bias in the test accuracy studies [17] (Table s3). When assessing evidence other than test accuracy in the studies of intervention, the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) was used [18] (Table s4). The GRADE framework was used to assess the overall certainty by evaluating the body of evidence for each outcome on the following domains: risk of bias, imprecision, inconsistency, indirectness, and publication bias [19, 20]. GRADE summary of findings tables were developed using the GRADEpro Guideline Development Tool [21].

Evidence to Recommendations

The panel considered the core elements of GRADE evidence in the decision process, including certainty of evidence and balance between desirable and undesirable effects. Additional domains were acknowledged where applicable (e.g., feasibility, resource use,

acceptability). For all recommendations, the expert panelists reached consensus. Voting rules were agreed on prior to the panel meeting for situations when consensus could not be reached.

As per GRADE methodology, recommendations were labeled as “strong” or “conditional.” The words “we recommend” indicate strong recommendations and “we suggest” indicate conditional recommendations. [Figure 2](#) provides the suggested interpretation of strong and weak recommendations for patients, clinicians, and healthcare policymakers. For recommendations where the comparators are not formally stated, the comparison of interest was implicitly referred to as “not using the test.” Some recommendations acknowledge a current “knowledge gap” and aim at avoiding premature favorable recommendations for test use and to avoid encouraging the rapid diffusion of potentially non-useful tests.


Revision Process

The draft guideline underwent review for approval by the Standards and Practice Guidelines Subcommittee of the IDSA and by the IDSA Board of Directors external to the guideline development panel. The guideline was reviewed and endorsed by ASM, PIDS and SHEA.

Updating Process

Regular, frequent screening of the literature will take place to determine the need for revisions based on the likelihood that any new data will have an impact on the recommendations. If necessary, the entire expert panel will be reconvened to discuss potential changes.

Figure 2. Approach and implications to rating the quality of evidence and strength of recommendations using the GRADE methodology (unrestricted use of the figure granted by the U.S. GRADE Network)



Search Results

Systematic review of the literature identified 30,645 references of which 163 informed the evidence base for this guideline recommendations (Figure s1). Characteristics of the included studies can be found in (Tables s5-s9).

Recommendations

Serology Testing in the First Two Weeks After Symptom Onset

Recommendation 1: The IDSA panel recommends against using serologic testing to diagnose SARS-CoV-2 infection during the first two weeks following symptom onset (strong recommendation, low certainty of evidence).

Remarks:

- Most studies included in this recommendation's literature review assessed unvaccinated individuals and so the panel's findings might not apply to individuals who have been vaccinated, especially with respect to specificity, rendering test accuracy worse than presented here.
- Similarly, in today's population there is a higher likelihood of prior SARS-CoV-2 infection than assessed in the included studies, which could also negatively affect specificity, rendering test accuracy worse than presented.
- Analogous to other respiratory viruses where non-serologic tests are preferred for diagnosis of acute infection, serologic testing should not be performed routinely for diagnosis of acute COVID-19.

Summary of evidence

We found no direct evidence of patient- or population-centered outcomes of testing versus no testing in symptomatic patients. Therefore, the panel relied on diagnostic test accuracy data to inform this recommendation.

Using the applied search strategy, we identified 111 studies [22-132] that assessed diagnostic test accuracy of serologic tests (IgM, IgG, IgM or IgG) compared to a SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test in the first two weeks after symptom onset. (Tables 1a-1c). Studies used varied sources for negative controls, including samples collected from healthy individuals, patients who had other respiratory or non-respiratory infections, patients with autoimmune diseases whose blood had been collected prior to the COVID-19 pandemic, symptomatic patients with negative NAAT for SARS-CoV-2, and/or patients hospitalized for reasons other than COVID-19. While most studies used case-control designs, some used longitudinal or cross-sectional cohort designs. For assays that detected and differentiated IgM from IgG using the same platform, an interpretation of “IgM or IgG” was considered a positive test (i.e., detection of one of the two immunoglobulins qualified as a positive test).

The total number of patient samples across all included studies ranged from 1,137 to 5,161 and 4,388 to 22,321, for sensitivity and specificity analyses, respectively (Figures s2a-s7b). The pooled sensitivity at one week after symptom onset ranged from 24 to 35% and at two weeks ranged from 64 to 74%, while the pooled specificity ranged from 98 to 99% (Tables 1a-1c).

The quality of evidence that informed sensitivity determinations was low, while the quality of evidence that informed specificity was moderate. Quality was rated downward for both sensitivity and specificity due to serious indirectness and unexplained inconsistency in sensitivity. Concerns with indirectness stemmed from the participants being evaluated in the pre-vaccination era, and before widespread infection. Given the very high global estimates of current SARS-CoV-2 seroprevalence, the test accuracy estimated from these studies would likely not reflect performance today.

Benefits and Harms

If performed within 14 days of onset of symptomatic infection, the low sensitivity of serologic tests can lead to a high number of falsely negative results. Individuals who test falsely negative would be classified as uninfected, when, in fact, they would be infected but they would not have developed a detectable antibody response. Although the specificity of serologic testing was calculated to be 98-99%, this likely does not represent performance in vaccinated and/or previously infected individuals, who were not assessed in the included studies. Tests with low specificity can lead to false positive result for recent infection at any time point of testing. A positive result can lead to the incorrect conclusion that an individual has been recently infected, thus eliminating the search for the true etiology of their symptoms, or resulting in unnecessary treatment or isolation.

Other considerations

IgM antibody responses often occur earlier after infection compared to IgG antibody responses. In contrast, with SARS-CoV-2 infection, there does not appear to be a substantial difference in the time after infection when IgM and IgG antibodies can be detected. At one week

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

after onset of symptoms, the pooled sensitivity for IgM tests was 27% compared to 24% for IgG tests, and at two weeks post onset of symptoms, the pooled sensitivity of IgM tests was 64% compared to 66% for IgG tests.

Conclusions and research needs for this recommendation

Serologic testing should not be performed routinely for diagnosis of acute COVID-19, analogous to the situation with other respiratory viruses. Achieving a better understanding of the role of serology as a correlate of protection with current circulating variants is a research need, especially in populations at highest risk of severe disease such as the elderly and immunocompromised. Correlation of viral RNA shedding and culture positivity (or other surrogate for infectivity) should be studied relative to immunoglobulin titers over time to help inform isolation guidelines for patients with COVID-19.

Last updated X Date and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

Table 1a. Performance of IgM Serologic Testing 1 and 2 Weeks after Onset of COVID-19 Symptoms

IgM	Week 1			Week 2		
Sensitivity	27% (95% CI: 22 to 34)			64% (95% CI: 58 to 70)		
Specificity	99% (95% CI: 98 to 99)			99% (95% CI: 98 to 100)		
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True positives (patients with COVID-19)	14 (11 to 17)	54 (44 to 68)	135 (110 to 170)	32 (29 to 35)	128 (116 to 140)	320 (290 to 350)
False negatives (patients incorrectly classified as not having COVID-19)	36 (33 to 39)	146 (132 to 156)	365 (330 to 390)	18 (15 to 21)	72 (60 to 84)	180 (150 to 210)
Quality of the evidence	50 studies, 2464 patients ⊕⊕○○ Low ^{b,c}			52 studies, 3481 patients ⊕⊕○○ Low ^{b,c}		
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True negatives (patients without COVID-19)	941 (931 to 941)	792 (784 to 792)	495 (490 to 495)	941 (931 to 950)	792 (784 to 800)	495 (490 to 500)
False positives (patients incorrectly classified as having COVID-19)	9 (9 to 19)	8 (8 to 16)	5 (5 to 10)	9 (0 to 19)	8 (0 to 16)	5 (0 to 10)
Quality of Evidence	50 studies, 10077 patients ⊕⊕⊕○ Moderate ^c			52 studies, 9956 patients ⊕⊕⊕○ Moderate ^c		

Explanations

- 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- Unexplained inconsistency in the sensitivity results.
- The population from the studies was mainly unvaccinated individuals and those without a prior known history of COVID-19, which may overestimate test accuracy within vaccinated or previously infected populations.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

Table 1b. Performance of IgG Serologic Testing 1 and 2 Weeks after Onset of COVID-19 Symptoms

IgG	Week 1			Week 2		
Sensitivity	24% (95% CI: 19 to 30)			66% (95% CI: 62 to 69)		
Specificity	99% (95% CI: 99 to 99)			99% (95% CI: 99 to 99)		
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True positives (patients with COVID-19)	12 (10 to 15)	48 (38 to 60)	120 (95 to 150)	33 (31 to 34)	132 (124 to 138)	330 (310 to 345)
False negatives (patients incorrectly classified as not having COVID-19)	38 (35 to 40)	152 (140 to 162)	380 (350 to 405)	17 (16 to 19)	68 (62 to 76)	170 (155 to 190)
Quality of the evidence	88 studies, 4250 patients ⊕⊕○○ Low ^{b,c}			90 studies, 5161 patients ⊕⊕○○ Low ^{b,c}		
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True negatives (patients without COVID-19)	941 (941 to 941)	792 (792 to 792)	495 (495 to 495)	941 (941 to 941)	792 (792 to 792)	495 (495 to 495)
False positives (patients incorrectly classified as having COVID-19)	9 (9 to 9)	8 (8 to 8)	5 (5 to 5)	9 (9 to 9)	8 (8 to 8)	5 (5 to 5)
Quality of Evidence	88 studies, 22321 patients ⊕⊕⊕○ Moderate ^c			90 studies, 19982 patients ⊕⊕⊕○ Moderate ^c		

Explanations

- 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- Unexplained inconsistency in the sensitivity results.
- The population from the studies was mainly unvaccinated individuals and those without a prior known history of COVID-19, which may overestimate test accuracy within vaccinated or previously infected populations.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

544 Table 1c. Performance of IgM or IgG Serologic Testing 1 and 2 Weeks after Onset of COVID-19 Symptoms

IgM or IgG	Week 1			Week 2		
Sensitivity	35% (95% CI: 27 to 44)			74% (95% CI: 69 to 79)		
Specificity	98% (95% CI: 96 to 99)			98% (95% CI: 96 to 99)		
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True positives (patients with COVID-19)	17 (14 to 22)	70 (54 to 88)	175 (135 to 220)	37 (34 to 40)	148 (138 to 158)	370 (345 to 395)
False negatives (patients incorrectly classified as not having COVID-19)	33 (28 to 36)	130 (112 to 146)	325 (280 to 365)	13 (10 to 16)	52 (42 to 62)	130 (105 to 155)
Quality of the evidence	28 studies, 1137 patients ⊕⊕○○ Low ^{b,c}			28 studies, 1685 patients ⊕⊕○○ Low ^{b,c}		
	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a	pre-test probability of 5% ^a	pre-test probability of 20% ^a	pre-test probability of 50% ^a
True negatives (patients without COVID-19)	931 (912 to 941)	784 (768 to 792)	490 (480 to 495)	931 (912 to 941)	784 (768 to 792)	490 (480 to 495)
False positives (patients incorrectly classified as having COVID-19)	19 (9 to 38)	16 (8 to 32)	10 (5 to 20)	19 (9 to 38)	16 (8 to 32)	10 (5 to 20)
Quality of Evidence	28 studies, 4466 patients ⊕⊕⊕○ Moderate ^c			28 studies, 4388 patients ⊕⊕⊕○ Moderate ^c		

545 Explanations

- 546 a. 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- 547 b. Unexplained inconsistency in the sensitivity results.
- 548 c. The population from the studies was mainly unvaccinated individuals and those without a prior known history of COVID-19, which may overestimate test accuracy within vaccinated or previously infected populations.
- 549
- 550
- 551

Serology Testing in Individuals with High Clinical Suspicion for SARS-CoV-2 Infection and Negative NAAT

Recommendation 2: The IDSA panel recommends against using IgG antibodies to provide evidence of COVID-19 in symptomatic patients with a high clinical suspicion and repeatedly negative NAAT (strong recommendation, very low certainty of evidence).

Remarks

- Contemporary populations are more likely to have had prior SARS-CoV-2 infection or vaccination than the populations assessed in the included studies, which could negatively affect pooled specificity calculations, rendering test accuracy worse than presented here.

Summary of the evidence

We identified 19 studies [30, 109, 130, 133-148] that compared the diagnostic test accuracy of serologic tests among patients with high clinical suspicion for COVID-19 and negative NAAT throughout the course of their illness. The percent of PCR-negative/IgG-positive test results ranged from 0% to 93% with most studies reporting this test result combination for fewer than 50% of samples. The percent of samples with PCR-negative/IgM-positive test results ranged from 2% to 83%, and the percent of samples with PCR-negative/IgM- or IgG-positive test results ranged from 11% to 62%. Finally, the percent of samples that yielded PCR-negative/total antibody-positive results ranged between 0% and 60%. These studies varied in terms of assay (chemistry, method, platform) and the timing of testing (e.g., <20 days versus >15 days) (Table S6).

The overall certainty of the evidence was very low due to concerns for risk of bias (case-control study design) and imprecision (as a result of small sample size). The use of clinical symptoms as a reference standard in some studies might have resulted in misclassification (i.e., labeling non-infected patients as true positive cases based on symptoms and serology alone).

Benefits and Harms

The panel's consensus opinion was that the clinical benefit of performing SARS-CoV-2 serologic testing in patients with high clinical suspicion for COVID-19 and repeatedly negative SARS-CoV-2 NAAT is low. This is because contemporary human populations have high SARS-CoV-2 seroprevalence due to natural, vaccine-induced, or hybrid immune responses. A positive serologic result for a symptomatic patient who tests repeatedly negative by NAAT may be attributed to vaccination and/or past infection as readily as to recent SARS-CoV-2 infection. Concluding that a positive serologic test is responsible for a patient's current symptoms can lead to misdiagnosis, particularly in periods when SARS-CoV-2 circulation is low and other respiratory virus circulation is high. In individuals who have not been vaccinated or previously infected (the population included in this recommendation's literature review), the negative predictive value of a SARS-CoV-2 serologic test is high when performed more than 2 weeks after symptom onset. In this instance, negative serologic results should prompt further evaluation of the patients' symptoms for alternative etiologies, if symptoms persist.

Other Considerations

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

594 No SARS-CoV-2 serologic test can differentiate between recent or remote infection.

595 Serologic tests cannot differentiate a serologic response to a vaccine antigen from a response
596 elicited by recent or remote infection.

597 ***Conclusions and research needs for this recommendation***

598 Assessing anti-SARS-CoV-2 antibodies provides no added benefit over repeat NAAT for
599 the diagnosis of acute COVID-19 and may lead to diagnostic uncertainty. Further research on the
600 role of serologic and immunologic testing for diagnosis or management of long-COVID may be
601 warranted.

602

603

Serologic Testing in Pediatric Patients with Suspicion of MIS-C

Recommendation 3: To assist with the diagnosis of multisystem inflammatory syndrome in children (MIS-C), the IDSA panel recommends using both IgG antibody testing and NAAT to provide evidence of current or recent past COVID-19 (strong recommendation, very low certainty of evidence).

Remarks:

- Combining IgG antibody testing with NAAT may improve both the ability to diagnose MIS-C and to rule it out, compared to using NAAT alone. Knowing the patient's vaccination and COVID-19 history may be helpful in interpreting serology results.
- Differentiating MIS-C from conditions with overlapping symptomatology, such as Kawasaki disease, is important because Kawasaki disease requires treatment with specific therapies such as intravenous immunoglobulin or rituximab if diagnosed. The two diseases also differ in terms of potential complications and need for long-term medication and follow-up.
- The January 2023 definition of MIS-C agreed upon by U.S. CDC and other public health officials requires evidence of current or recent SARS-CoV-2 infection by PCR, antigen, or serologic testing [3].

Summary of the evidence

We identified 10 case series [149-158] that evaluated the use of SARS-CoV-2 serologic tests in pediatric patients presenting with signs of multisystem inflammatory syndrome in children (MIS-C) (Table s7). The case definitions of this inflammatory syndrome, typically manifesting with

fever and shock similar to Kawasaki Disease, varied across studies. Most reports were from early in the pandemic and did not require laboratory evidence of SARS-CoV-2 infection to define the syndrome. However, these studies reported a higher rate of MIS-C diagnosis when IgG antibodies were added to NAAT compared to using NAAT alone. NAAT was positive in ~30-50% of cases in these studies, while IgG antibodies were positive in >80% cases in most studies. The major limitation of the evidence is that not all case series specified the timing of testing (either NAAT or serology) with respect to symptom onset. In addition, the type of serologic test utilized and epidemiologic links to COVID-19 cases were also not uniformly specified. The overall quality of evidence was very low due to the limitations of the case series study design and serious risk of bias. Even with very low certainty evidence, the panel issued a strong recommendation given the potentially catastrophic consequences of missing a diagnosis of MIS-C.

Benefits and Harms

The diagnosis of MIS-C is important to provide appropriate treatment and follow up care for children, but no specific test is available to confirm this diagnosis. Another acute inflammatory syndrome in children, Kawasaki Disease, which generally affects children less than 5 years of age, can present with symptoms very similar to those of MIS-C. Although the initial treatment of both MIS-C and Kawasaki Disease typically includes supportive care and hospitalization, the differentiation of these two syndromes is important because Kawasaki disease requires hospitalization and treatment with specific therapies such as intravenous immunoglobulin or rituximab if diagnosed. The two diseases also differ in terms of potential complications and need for long term medication and follow up. The management of children

with MIS-C usually requires supportive care, including hospitalization and treatment of shock and respiratory distress, evaluation of cardiac function, and administration of medications that decrease inflammation. Diagnostic tools including serology to help exclude the diagnosis of MIS-C can therefore be helpful and important, but serologic testing may not be helpful in the actual diagnosis of MIS-C as many children have serologic evidence of past COVID-19 disease and/or vaccination. Further, given the high seroprevalence of antibodies to SARS-CoV-2 in the pediatric population, a negative serologic test result provides stronger evidence against a diagnosis of MIS-C than a positive result provides evidence for MIS-C. Although the certainty of evidence to inform this recommendation was very low, the panel concluded that the potential harm associated with a misdiagnosis of MIS-C warranted a strong recommendation for serologic testing together with NAAT in suspected cases.

Other Considerations

The clinical description and definition of MIS-C, as well as other SARS-CoV-2-associated inflammatory syndromes in children and adults, have varied over the pandemic and across countries and regions. Different clinical criteria with or without laboratory evidence of infection make comparisons of early studies problematic. It should be noted that the 2023 CDC definition of a confirmed case of MIS-C [3] requires meeting clinical and laboratory criteria; the latter include detection of SARS-CoV-2 RNA or antigen in a specimen up to 60 days before or during hospitalization or post-mortem, or detection of SARS-CoV-2 specific antibodies in serum, plasma, or whole blood associated with the current illness resulting in or during hospitalization [159]. Assessment of the reliability, sensitivity, and specificity of laboratory diagnostic criteria to

document MIS-C will be difficult in the future because laboratory criteria are now required for diagnosis, and because case rates of MIS-C are falling. Given that pediatric seroprevalence for SARS-CoV-2 was 96.3% in December 2022, it is not surprising that 99% of recent U.S. cases of MIS-C are seropositive for SARS-CoV-2 [160].

Conclusions and research needs for this recommendation

Acute febrile inflammatory syndromes in children are challenging to diagnose, but updated definitions of MIS-C are making this diagnosis more uniform. Differentiation of Kawasaki Disease from MIS-C will continue to be an issue, particularly in young children. In addition, changes in MIS-C epidemiology have been seen, with fewer cases of MIS-C now reported in association with new SARS-CoV-2 variants [161]. In addition, COVID-19 vaccination is associated with reduced incidence of MIS-C, especially if two doses are given [162]. Continued investigation of the epidemiology and treatment of MIS-C is warranted.

Serologic Testing to Assess Previous SARS-CoV-2 Infection – Antibody Class

Recommendation 4: When evidence of previous SARS-CoV-2 infection is desired, the IDSA panel suggests testing for SARS-CoV-2 IgG, IgG/IgM, or total antibodies three to five weeks after symptom onset and suggests against testing for SARS-CoV-2 IgM (conditional recommendation, low certainty of evidence).

Remarks:

- SARS-CoV-2 NAAT and antigen tests have superior performance characteristics for diagnosis of COVID-19, compared to serologic testing.
- There are very limited situations in which SARS-CoV-2 antibody testing might be useful (e.g., in helping to diagnose MIS-C).

Summary of the evidence

Using our search strategy, 53 studies [22-24, 29, 30, 34, 35, 38-42, 47, 51, 53, 54, 57, 58, 60-63, 66, 67, 71, 73, 76, 82, 83, 90, 91, 93, 94, 98, 102, 105, 106, 109, 110, 112, 114, 117, 118, 121, 129, 134, 163-169] were identified that assessed the diagnostic accuracy of serologic tests (IgM, IgG, IgM or IgG, and total antibodies) between weeks 3 and 8 after symptom onset compared to SARS-CoV-2 NAAT (Tables 2a-2d). Many of these same studies also informed Recommendation 1 in this guideline.

The number of samples in these studies that were included in analyses of sensitivity ranged from 44 to 2,591 and the number included in the specificity analyses ranged from 386 to

10,537 (Figures s8a-s28b). The pooled sensitivity at week three after symptom onset ranged from 83% to 93%, at week four from 86% to 95%, at week five from 89% to 95%, at week six from 85% to 97%, at week seven between 73% and 92%, and at week eight between 73% and 94%, while the pooled specificity ranged from 98% to 100% (Tables 2a-2d). When analyzed by antibody class, IgM consistently demonstrated the lowest analytical sensitivity compared with IgG alone, IgM/IgG or total antibodies.

The certainty of evidence that informed sensitivity determinations was low, while the certainty of evidence to inform specificity determinations was moderate. Quality was rated downward for both sensitivity and specificity due to serious indirectness, and due to unexplained inconsistency in sensitivity. Concerns with indirectness stemmed from the fact that study populations dated mainly from the pre-vaccination era, and preceded infection with currently circulating viral variants. Thus, the analyses presented here may overestimate test accuracy in contemporary populations with high SARS-CoV-2 seroprevalence.

Benefits and Harms

There are limited data on antibody level stability after natural infection, and even less on interpretation of antibody levels in the setting of a patient who has been both vaccinated and infected. Clinicians must be aware of the limitations of antibody testing, as well as the impact of patient vaccination history. Most published studies were performed early in the pandemic, before widespread vaccination or large numbers of infected individuals. In the studies included in the literature review for this recommendation, all antibody classes had similar specificities up to 8 weeks, but the lack of sensitivity of IgM-only assays means that patients would be incorrectly classified as not having been infected.

727 ***Other considerations***

728 Antibody testing to demonstrate prior infection may be helpful in limited scenarios.
729 These could include evaluating patients with possible MIS-C or assessing immune response in
730 immunocompromised patients with ongoing PCR positivity who might be candidates for
731 monoclonal antibody or convalescent antibody therapy, if effective therapy were available,
732 especially in setting of limited supplies.

733

734 ***Conclusions and research needs for this recommendation***

735 Antibody testing for respiratory viruses is not part of routine clinical care and should not
736 be used to guide decisions regarding vaccination or non-pharmacologic infection prevention
737 precautions. Further study is needed to determine duration of antibody response to either
738 vaccination or infection, and to clarify the clinical scenarios in which measuring these analytes
739 can benefit individual patients or populations.

740 Table 2a. Performance of IgM Serologic Testing in Weeks 3 to 8 after Onset of COVID-19 Symptoms

IgM	Week 3			Week 4			Week 5			Week 6			Week 7			Week 8		
Sensitivity	83% (95% CI: 74 to 90)			86% (95% CI: 75 to 93)			89% (95% CI: 75 to 96)			85% (95% CI: 75 to 91)			73% (95% CI: 60 to 83)			73% (95% CI: 62 to 82)		
Specificity	99% (95% CI: 98 to 100)			99% (95% CI: 97 to 100)			99% (95% CI: 97 to 100)			99% (95% CI: 94 to 100)			100% (95% CI: 31 to 100)			99% (95% CI: 57 to 100)		
Outcome	Effect per 1,000 patients tested																	
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True positives (patients with COVID-19)	42 (37 to 45)	166 (148 to 180)	415 (370 to 450)	43 (38 to 47)	172 (150 to 186)	430 (375 to 465)	45 (38 to 48)	178 (150 to 192)	445 (375 to 480)	43 (38 to 46)	170 (150 to 185)	425 (375 to 455)	37 (30 to 42)	146 (120 to 160)	365 (300 to 410)	37 (31 to 41)	146 (124 to 160)	365 (310 to 410)
False negatives (patients incorrectly classified as not having COVID-19)	8 (5 to 13)	34 (20 to 52)	85 (50 to 130)	7 (3 to 12)	28 (14 to 50)	70 (35 to 125)	5 (4 to 12)	22 (12 to 50)	55 (20 to 125)	7 (4 to 12)	30 (18 to 50)	75 (45 to 125)	13 (8 to 20)	54 (34 to 80)	135 (85 to 200)	13 (9 to 19)	54 (36 to 76)	135 (90 to 190)
Quality of the evidence	33 studies, 2054 patients ⊕⊕○○ Low ^{b,c}			17 studies, 1211 patients ⊕⊕○○ Low ^{b,c}			10 studies, 890 patients ⊕⊕○○ Low ^{b,c}			10 studies, 693 patients ⊕⊕○○ Low ^{b,c}			4 studies, 337 patients ⊕⊕○○ Low ^{b,c}			4 studies, 328 patients ⊕⊕○○ Low ^{b,c}		
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True negatives (patients without COVID-19)	941 (931 to 950)	792 (784 to 800)	495 (490 to 500)	941 (922 to 950)	792 (776 to 800)	495 (485 to 500)	941 (922 to 950)	792 (776 to 800)	495 (485 to 500)	941 (893 to 950)	792 (752 to 800)	495 (470 to 500)	950 (925 to 950)	800 (780 to 800)	500 (450 to 500)	941 (925 to 950)	792 (780 to 800)	495 (450 to 500)
False positives (patients incorrectly classified as having COVID-19)	9 (9 to 19)	8 (0 to 16)	5 (0 to 10)	9 (0 to 28)	8 (0 to 24)	5 (0 to 15)	9 (0 to 28)	8 (0 to 24)	5 (0 to 15)	9 (0 to 28)	8 (0 to 24)	5 (0 to 15)	0 (0 to 57)	0 (0 to 48)	0 (0 to 655)	0 (0 to 552)	0 (0 to 345)	9 (0 to 408)
Quality of Evidence	33 studies, 7640 patients ⊕⊕⊕○ Moderate ^c			17 studies, 5095 patients ⊕⊕⊕○ Moderate ^c			10 studies, 2457 patients ⊕⊕⊕○ Moderate ^c			10 studies, 3687 patients ⊕⊕⊕○ Moderate ^c			4 studies, 552 patients ⊕⊕⊕○ Moderate ^c			4 studies, 1919 patients ⊕⊕⊕○ Moderate ^c		

741 Explanations

- 742 a. 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of
743 highly transmissible variants (e.g., first Omicron surge).

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- b. Unexplained inconsistency in the sensitivity results
- c. These studies were conducted mainly with populations who had not been vaccinated and before emergence of currently circulating viral variants. Therefore, the estimates presented above may overestimate test accuracy in contemporary populations with high seroprevalence to SARS-CoV-2.

Table 2b. Performance of IgG Serologic Tests Weeks 3 to 8 after Onset of COVID-19 Symptoms

IgG	Week 3			Week 4			Week 5			Week 6			Week 7			Week 8		
Sensitivity	89% (95% CI: 85 to 92)			95% (95% CI: 90 to 98)			95% (95% CI: 90 to 98)			97% (95% CI: 91 to 99)			92% (95% CI: 88 to 95)			94% (95% CI: 85 to 98)		
Specificity	99% (95% CI: 99 to 99)			99% (95% CI: 98 to 0.99)			99% (95% CI: 98 to 0.99)			99% (95% CI: 98 to 100)			99% (95% CI: 98 to 100)			99% (95% CI: 97 to 100)		
Outcome	Effect per 1,000 patients tested																	
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True positives (patients with COVID-19)	45 (43 to 46)	178 (170 to 184)	445 (425 to 460)	48 (45 to 49)	190 (180 to 196)	475 (450 to 490)	48 (45 to 49)	190 (180 to 196)	475 (450 to 490)	49 (46 to 50)	194 (185 to 199)	485 (455 to 495)	46 (44 to 48)	184 (176 to 190)	460 (440 to 475)	47 (43 to 49)	188 (170 to 195)	470 (425 to 490)
False negatives (patients incorrectly classified as not having COVID-19)	5 (4 to 7)	22 (16 to 30)	55 (40 to 75)	2 (1 to 5)	10 (4 to 20)	25 (10 to 50)	2 (1 to 5)	10 (4 to 20)	25 (10 to 50)	1 (0 to 4)	6 (2 to 18)	15 (5 to 45)	4 (2 to 6)	16 (10 to 24)	40 (25 to 60)	3 (1 to 7)	12 (4 to 30)	30 (10 to 75)
Quality of the evidence	47 studies, 2591 patients ⊕⊕○○ Low ^{b,c}			27 studies, 1545 patients ⊕⊕○○ Low ^{b,c}			16 studies, 918 patients ⊕⊕○○ Low ^{b,c}			14 studies, 832 patients s ⊕⊕○○ Low ^{b,c}			5 studies, 246 patients ⊕⊕○○ Low ^{b,c}			3 studies, 251 patients ⊕⊕○○ Low ^{b,c}		
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True negatives (patients without COVID-19)	941 (941 to 941)	792 (792 to 792)	495 (495 to 495)	941 (931 to 941)	792 (784 to 792)	495 (490 to 495)	941 (931 to 941)	792 (784 to 792)	495 (490 to 495)	941 (931 to 941)	792 (784 to 792)	495 (490 to 495)	941 (931 to 941)	792 (784 to 792)	495 (490 to 495)	941 (922 to 950)	792 (776 to 800)	495 (485 to 495)
False positives (patients incorrectly classified as having COVID-19)	9 (9 to 9)	8 (8 to 8)	5 (5 to 5)	9 (9 to 9)	8 (8 to 16)	5 (5 to 10)	9 (9 to 9)	8 (8 to 16)	5 (5 to 10)	9 (9 to 19)	8 (0 to 16)	5 (0 to 10)	9 (0 to 19)	8 (0 to 16)	5 (0 to 10)	9 (0 to 28)	8 (0 to 24)	5 (0 to 15)

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.

Please check website for most updated version of these guidelines.

Quality of Evidence	47 studies, 10537 patients ⊕⊕⊕○ Moderate ^c	27 studies, 6323 patients ⊕⊕⊕○ Moderate ^c	16 studies, 3240 patients ⊕⊕⊕○ Moderate ^c	14 studies, 3944 patients ⊕⊕⊕○ Moderate ^c	5 studies, 696 patients ⊕⊕⊕○ Moderate ^c	3 studies, 1082 patients ⊕⊕⊕○ Moderate ^c
---------------------	---	--	--	--	--	---

Explanations

- 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- Unexplained inconsistency in the sensitivity results
- These studies were conducted mainly with populations who had not been vaccinated and before emergence of currently circulating viral variants. Therefore, the estimates presented above may overestimate test accuracy in contemporary populations with high seroprevalence to SARS-CoV-2.

Table 2c. Performance of IgM or IgG Serologic Tests 3 to 8 Weeks after Onset of COVID-19 Symptoms

IgM or IgG	Week 3			Week 4			Week 5			Week 6			Week 7			Week 8		
Sensitivity	93% (95% CI: 88 to 96)			93% (95% CI:83 to 98)			94% (95% CI: 88 to 97)			96% (95% CI: 80 to 99)			NR			NR		
Specificity	98% (95% CI: 96 to 99)			99% (95% CI: 94 to 100)			99% (95% CI: 95 to 100)			99% (95% CI: 89 to 100)			NR			NR		
Outcome	Effect per 1,000 patients tested																	
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True positives (patients with COVID-19)	47 (4 to 48)	186 (176 to 192)	465 (440 to 480)	47 (42 to 49)	186 (166 to 196)	465 (415 to 490)	47 (44 to 49)	188 (176 to 194)	470 (440 to 485)	48 (40 to 50)	192 (168 to 199)	480 (405 to 495)	NR	NR	NR	NR	NR	NR
False negatives (patients incorrectly classified as not having COVID-19)	3 (2 to 6)	14 (8 to 24)	35 (20 to 60)	3 (1 to 8)	14 (4 to 34)	14 (4 to 34)	3 (1 to 6)	12 (6 to 24)	30 (15 to 60)	2 (0 to 10)	8 (2 to 40)	20 (5 to 100)	NR	NR	NR	NR	NR	NR
Quality of the evidence	17 studies, 646 patients ⊕⊕○○ Low ^{b,c}			6 studies, 363 patients ⊕⊕○○ Low ^{b,c}			6 studies, 442 patients ⊕⊕○○ Low ^{b,c}			3 studies, 91 patients ⊕⊕○○ Low ^{b,c}			NR			NR		
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True negatives (patients without COVID-19)	931 (912 to 941)	784 (768 to 792)	490 (480 to 495)	941 (893 to 950)	792 (752 to 800)	495 (470 to 500)	941 (903 to 950)	792 (760 to 800)	495 (475 to 500)	941 (845 to 950)	792 (710 to 800)	495 (445 to 500)	NR	NR	NR	NR	NR	NR

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

False positives (patients incorrectly classified as having COVID-19)	19 (9 to 38)	16 (8 to 3 2)	10 (5 to 20)	9 (0 to 57)	8 (0 to 48)	5 (0 to 30)	9 (0 to 47)	8 (0 to 40)	5 (0 to 25)	9 (0 to 105)	8 (0 to 88)	5 (0 to 55)	NR	NR	NR	NR	NR	NR
Quality of Evidence	17 studies, 3075 patients ⊕⊕⊕○ Moderate ^c			6 studies, 1344 patients ⊕⊕⊕○ Moderate ^c			6 studies, 950 patients ⊕⊕⊕○ Moderate ^c			3 studies, 450 patients ⊕⊕⊕○ Moderate ^c			NR			NR		

Explanations

- 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- Unexplained inconsistency in the sensitivity results
- These studies were conducted mainly with populations who had not been vaccinated and before emergence of currently circulating viral variants. Therefore, the estimates presented above may overestimate test accuracy in contemporary populations with high seroprevalence to SARS-CoV-2.

Last updated X Date and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

764 Table 2d. Performance of Total Antibodies Serologic Tests Weeks 3 to 8 after Onset of COVID-19 Symptoms

Total Antibodies	Week 3			Week 4			Week 5			Week 6			Week 7			Week 8		
Sensitivity	92% (95% CI: 88 to 94)			95% (95% CI: 92 to 97)			95% (95% CI: 91 to 97)			96% (95% CI: 90 to 99)			88% (95% CI: 71 to 95)			NR		
Specificity	100% (95% CI: 99 to 100)			99% (95% CI: 99 to 100)			99% (95% CI: 98 to 100)			99% (95% CI: 98 to 100)			100% (95% CI: 87 to 100)			NR		
Outcome	Effect per 1,000 patients tested																	
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True positives (patients with COVID-19)	46 (44 to 47)	184 (176 to 188)	460 (440 to 470)	48 (46 to 49)	190 (184 to 194)	475 (460 to 485)	48 (46 to 49)	190 (182 to 194)	475 (455 to 485)	48 (45 to 50)	192 (180 to 198)	480 (450 to 490)	44 (36 to 48)	176 (142 to 190)	440 (355 to 475)	NR	NR	NR
False negatives (patients incorrectly classified as not having COVID-19)	4 (3 to 6)	16 (12 to 24)	40 (30 to 60)	2 (1 to 4)	10 (6 to 16)	25 (15 to 40)	2 (1 to 4)	10 (6 to 18)	25 (15 to 45)	2 (0 to 5)	8 (2 to 20)	20 (5 to 50)	6 (2 to 14)	24 (10 to 58)	60 (25 to 145)	NR	NR	NR
Quality of the evidence	23 studies, 1177 patients ⊕⊕○○ Low ^{b,c}			14 studies, 706 patients ⊕⊕⊕○ Moderate ^c			11 studies, 479 patients ⊕⊕⊕○ Moderate ^c			8 studies, 239 patients ⊕⊕⊕○ Moderate ^c			3 studies, 44 patients ⊕⊕⊕○ Moderate ^c			NR		
	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a	5% ^a	20% ^a	50% ^a
True negatives (patients without COVID-19)	950 (941 to 950)	800 (792 to 800)	500 (495 to 500)	941 (941 to 950)	792 (792 to 800)	495 (495 to 500)	941 (931 to 950)	792 (784 to 800)	495 (490 to 500)	941 (931 to 950)	792 (784 to 800)	495 (490 to 500)	950 (827 to 950)	800 (696 to 800)	500 (435 to 500)	NR	NR	NR
False positives (patients incorrectly	0 (0 to 9)	0 (0 to 8)	0 (0 to 5)	9 (0 to 9)	8 (0 to 8)	5 (0 to 5)	9 (0 to 18)	8 (0 to 15)	5 (0 to 19)	9 (0 to 19)	8 (0 to 16)	5 (0 to 10)	0 (0 to 123)	0 (0 to 104)	0 (0 to 65)	NR	NR	NR

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

classified as having COVID-19)																		
Quality of Evidence	23 studies, 4991 patients ⊕⊕⊕○ Moderate ^c	14 studies, 2949 patients ⊕⊕⊕○ Moderate ^c	11 studies, 2109 patients ⊕⊕⊕○ Moderate ^c	8 studies, 1558 patients ⊕⊕⊕○ Moderate ^c	3 studies, 386 patients ⊕⊕⊕○ Moderate ^c	NR												

Explanations

- 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission rates, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly transmissible variants (e.g., first Omicron surge).
- Unexplained inconsistency in the sensitivity results
- These studies were conducted mainly with populations who had not been vaccinated and before emergence of currently circulating viral variants. Therefore, the estimates presented above may overestimate test accuracy in contemporary populations with high seroprevalence to SARS-CoV-2.

771

772 Serologic Testing to Assess Previous SARS-CoV-2 infection – Antibody
773 Target

774 **Recommendation 5:**

- 775 • When evidence of prior SARS-CoV-2 infection is desired, the IDSA panel suggests
776 using serologic assays that target nucleocapsid protein rather than spike protein
777 (conditional recommendation, low certainty of evidence).

778 **Remarks:**

- 779 • Most available vaccines result in formation of only anti-spike antibodies but
780 some (e.g., CoronaVac and BBIBP-CorV, manufactured by Sinovac and
781 Sinopharm, respectively) which contain inactivated whole virus, can also result in
782 formation of anti-nucleocapsid antibodies [4].
- 783 • Given the high prevalence of vaccination in most populations and the
784 persistence of anti-spike antibodies over time, detection of anti-spike antibodies
785 has low positive predictive value for diagnosis of recent COVID-19 in most
786 individuals.

787

788 ***Summary of the evidence***

789 We identified 6 studies [55, 69, 109, 170-172] that assessed in the same study population
790 the diagnostic test accuracy of serologic tests that target spike and nucleocapsid proteins and
791 compared the results of a recent (past 1-8 weeks) positive SARS-CoV-2 NAAT (Tables 3a-3b). All

six studies included results for IgG, and one study also assessed IgM [171]. The sensitivity of assays targeting spike were 69% (95% CI: 65 to 73) and 69% (95% CI: 49 to 84) for IgM and IgG, respectively. The sensitivity of assays targeting nucleocapsid were 63% (95% CI: 58 to 69) and 75% (95% CI: 58 to 87) for IgM and IgG, respectively. The specificity ranged between 99% and 100% for both targets with IgM and IgG (Figures 29a-30b).

The certainty of evidence that informed sensitivity and specificity for IgM was low, and the certainty of evidence that informed sensitivity and specificity for IgG was low and moderate, respectively. The certainty was downgraded for concerns related to indirectness and imprecision (single study for IgM) and unexplained inconsistency (sensitivity of IgG). Indirectness is a concern because these studies were conducted primarily in an unvaccinated population and with SARS-CoV-2 variants that no longer predominate in the population. Together, these factors may overestimate test accuracy for the current population, which has high seroprevalence for SARS-CoV-2 due to vaccination and/or natural infection. We did not lower the certainty for indirectness of comparison as the studies tested the same population with the same anti-spike and anti-nucleocapsid antibody assays.

Benefits and Harms

Regardless of target, serologic assays are likely to underestimate recent infection by SARS-CoV-2. While specificity was high in the studies evaluated, studies were conducted before widespread SARS-CoV-2 vaccination and infection. Specificity of anti-spike IgG as a marker of prior infection is expected to be low when testing the current, highly vaccinated population, as the spike antigen is the target for most available vaccines. In contrast, a positive result for IgM or IgG nucleocapsid antibodies is indicative of prior infection in most individuals, with the exception

of those who received a vaccine that resulted in formation of anti-nucleocapsid antibodies, such as the inactivated whole-virus vaccines available outside the U.S.

Other considerations

While not specifically evaluated, waning of antibody levels over time after natural infection and vaccination has been noted. In particular, nucleocapsid-specific antibodies may be more short-lived in both immunocompetent [173] and immunocompromised patients [174], although comparing results between studies is often difficult due to the different antibody assays used. As such, timing of antibody testing is critical to the negative predictive value of the test and should ideally be performed within 3-4 weeks of symptom onset.

Conclusions and research needs for this recommendation

Sensitivity and specificity of nucleocapsid and spike antibody tests are similar, although interpretation of results as indicative of past infection (anti-nucleocapsid) versus past infection or vaccination (anti-spike) requires that clinicians know and understand the antibody target of the test that is used. While NAAT remains the recommended approach for diagnosis of COVID-19, detection of anti-nucleocapsid IgG, combination IgG/IgM, or total antibodies may be useful for determining recent past infection in selected clinical situations, e.g., MIS-C (see Recommendation 3 above.)

Last updated X Date and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

833 Table 3a. Performance of IgM Serologic Tests that Target the Spike versus Nucleocapsid Antigens

	IgM Spike							IgM Nucleocapsid						
Sensitivity	69% (95% CI: 65 to 73)							63% (95% CI: 58 to 69)						
Specificity	100% (95% CI: 100 to 100)							100% (95% CI: 100 to 100)						
Outcome	No of studies (No of patients)	Study design	Factors that may decrease certainty of evidence					Effect per 1,000 patients tested						Test accuracy CoE
								pre-test probability of 5% ^a		pre-test probability of 20% ^a		pre-test probability of 50% ^a		
			Risk of bias	Indirectness	Inconsistency	Imprecision	Publication bias	IgM Spike	IgM Nucleocapsid	IgM Spike	IgM Nucleocapsid	IgM Spike	IgM Nucleocapsid	
True positives (patients with COVID-19)	1 studies 909 patients ^b	case-control type studies	Not serious	serious ^c	not serious	serious ^d	none	34 (33 to 37)	32 (29 to 34)	138 (130 to 146)	126 (116 to 138)	345 (325 to 365)	315 (290 to 345)	⊕⊕○○ Low
								2 more TP in IgM Spike		12 more TP in IgM Spike		30 more TP in IgM Spike		
								16 (13 to 17)	18 (16 to 21)	62 (54 to 70)	74 (62 to 84)	155 (135 to 175)	185 (155 to 210)	
False negatives (patients incorrectly classified as not having COVID-19)								2 fewer FN in IgM Spike		12 fewer FN in IgM Spike		30 fewer FN in IgM Spike		
True negatives (patients without COVID-19)	1 studies 14778 patients ^e	case-control type studies	Not serious	serious ^c	not serious	serious ^d	none	950 (950 to 950)	950 (950 to 950)	800 (800 to 800)	800 (800 to 800)	500 (500 to 500)	500 (500 to 500)	⊕⊕○○ Low
								0 fewer TN in IgM Spike		0 fewer TN in IgM Spike		0 fewer TN in IgM Spike		

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

False positives (patients incorrectly classified as having COVID-19)								0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	
								0 fewer FP in IgM Spike	0 fewer FP in IgM Spike	0 fewer FP in IgM Spike				

834 **Explanations**

- 835 a. 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission levels, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly
836 transmissible variants (e.g., first Omicron surge).
837 b. Out of the 909 patients, 606 samples were tested for IgM Spike and 303 were tested for IgM nucleocapsid
838 c. There is no indirectness of comparison since these studies compared the two targets within the same population and assay. However, the population from the studies is mainly individuals with pre-vaccination, and pre-
839 currently circulating variants infection, which may overestimate the test accuracy in contemporary populations.
840 d. Serious imprecision due to low number of studies and events.
841 e. Out of the 14,778 patients, 9852 samples were tested for IgM anti-spike antibodies and 4926 were tested for IgM anti-nucleocapsid antibodies.

842

843

844

845

846

847

848

849

850

851

852 Table 3b. Performance of IgG Serologic Tests that Target the Spike versus the Nucleocapsid Antigen

	IgG Spike	IgG Nucleocapsid
--	-----------	------------------

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

Sensitivity	69% (95% CI: 49 to 84)							75% (95% CI: 58 to 87)						
Specificity	99% (95% CI: 99 to 100)							99% (95% CI: 98 to 99)						
Outcome	№ of studies (№ of patients)	Study design	Factors that may decrease certainty of evidence					Effect per 1,000 patients tested						Test accuracy CoE
								pre-test probability of 5% a		pre-test probability of 20% a		pre-test probability of 50% a		
			Risk of bias	Indirectness	Inconsistency	Imprecision	Publication bias	IgG Spike	IgG Nucleocapsid	IgG Spike	IgG Nucleocapsid	IgG Spike	IgG Nucleocapsid	
True positives (patients with COVID-19)	6 studies 2379 patients ^b	case-control type accuracy study	not serious	serious ^c	serious ^d	not serious	none	34 (25 to 42)	38 (29 to 44)	138 (98 to 168)	150 (116 to 174)	345 (245 to 420)	375 (290 to 435)	⊕⊕○○ Low
4 fewer TP in IgG Spike								12 fewer TP in IgG Spike		30 fewer TP in IgG Spike				
False negatives (patients incorrectly classified as not having COVID-19)								16 (8 to 25)	12 (6 to 21)	62 (32 to 102)	50 (26 to 84)	155 (80 to 255)	125 (65 to 210)	
4 more FN in IgG Spike								12 more FN in IgG Spike		30 more FN in IgG Spike				
True negatives (patients without COVID-19)	6 studies 21495 patients ^e	cohort & case-control type studies	not serious	serious ^c	not serious	not serious	none	941 (941 to 950)	941 (931 to 941)	792 (792 to 800)	792 (784 to 792)	495 (495 to 500)	495 (490 to 495)	⊕⊕⊕○ Moderate
0 fewer TN in IgG Spike								0 fewer TN in IgG Spike		0 fewer TN in IgG Spike				
False positives (patients incorrectly classified as having COVID-19)								9 (0 to 9)	9 (9 to 19)	8 (0 to 8)	8 (8 to 16)	5 (0 to 5)	5 (5 to 10)	
0 fewer FP in IgG Spike								0 fewer FP in IgG Spike		0 fewer FP in IgG Spike				

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

853 **Explanations**

- 854 a. 5%, 20% and 50% pre-test probabilities were used to account for low and moderate community transmission levels, for cases of known close contact (e.g., household contacts), and for outbreaks or surges of highly
855 transmissible variants (e.g., first Omicron surge).
- 856 b. Out of the 2379 patient samples, 1339 samples were tested for IgM anti-spike antibodies and 1040 were tested for IgM anti-nucleocapsid antibodies
- 857 f. There is no indirectness of comparison since these studies compared the two targets within the same population and assay. However, the population from the studies is mainly individuals pre-vaccination, and pre-
858 infection with currently circulating variants, which may overestimate the test accuracy in contemporary populations.
- 859 c. Unexplained inconsistency in the sensitivity results
- 860 d. Out of the 21,495 patient samples, 13,194 samples were tested for IgM anti-spike antibodies and 8301 were tested for IgM anti-nucleocapsid antibodies.

Serologic Testing to Improve Outcomes in Individuals with History of Vaccination or Previous Infection

Recommendation 6:

- In individuals with previous SARS-CoV-2 infection or vaccination, the IDSA panel suggests against routine serologic testing given no demonstrated benefit to improving patient outcomes (conditional recommendation, very low certainty of evidence).

Remarks

- Serologic testing may be useful for diagnosing MIS-C in pediatric patients, especially when NAAT or antigen testing is negative, to provide evidence of recent COVID-19 (see Recommendation 3 above).
- A negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy such as convalescent plasma or monoclonal antibodies, if such therapies were available, or to prioritize administration of monoclonal therapies when supplies are limited.

Summary of the evidence:

Studies addressing natural infection:

We found no direct evidence to correlate serologic testing with improved outcomes at the population or individual level for persons with prior COVID-19. We identified 6 studies [175-180], 5 cohort and 1 case control study [177] that evaluated the relationship between antibody level (e.g., seropositivity) and decreased SARS-CoV-2 reinfection rates. This included five studies that assessed binding antibodies and one that assessed neutralizing antibodies [175]. Across the cohort studies, subjects with a seropositive result post-infection appeared to have a lower likelihood of developing re-infection. In the case control study [177], doubling of the

antibody level was associated with reduced odds of reinfection. These studies, however, varied in the definition of reinfection, the timing of testing in relation to history of COVID-19, the antibody test used, and the comparison groups. (Table s8).

Studies addressing vaccination:

We identified 10 post-vaccination studies [181-190] including 6 cohort studies, 1 clinical trial [184], 1 systematic review [183], and 2 case control studies [182, 189] that evaluated the relationship between binding antibody (bAb) level and SARS-CoV-2 breakthrough infection rates [189, 190]. Results were inconsistent: 5 studies reported a correlation between seropositivity and decreased SARS-CoV-2 infection rates, while 2 [187, 188] reported no difference in infection rates between those who had seroconverted after vaccination and those who had not. Of note, the number of breakthrough infections in some studies was small, and several studies focused on patient populations with immunocompromising conditions.

The presence of neutralizing antibodies (nAbs) appears to correlate with protection against breakthrough infection based on a clinical trial and a systematic review (Table s9). However, a single tier or threshold antibody level that is predictive of protection has not been identified, and unless calibrated to a common reference standard, quantitative results are not commutable across assays (See Other Considerations below). We also did not identify any studies measuring the predictive value of hybrid immunity (i.e., serologic testing in individuals with confirmed previous SARS-CoV-2 infection and COVID-19 vaccination).

Summary statement:

The overall quality of evidence was very low due to risk of bias (Table s4), indirectness, and imprecision. There is indirectness in comparison, as the included studies only describe differences between subjects who underwent serologic testing. It is unclear if patient outcomes are any different because of testing (i.e., if test

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

results would lead to any meaningful changes in care or outcomes). It is unclear therefore if serologic testing provides any benefit for patient care decisions or to patients.

Benefits and Harms

Anti-SARS CoV-2 antibody tests help identify people who may have been infected with SARS-CoV-2 or were vaccinated. However, a universal antibody level that is predictive of protection from re-infection after infection or vaccination has not been identified. The panel did not identify any benefits to antibody testing in most individuals to inform management decisions.

There may be selected scenarios for immunocompromised hosts, however, where serologic testing could be considered. One example is for patients with symptomatic COVID-19 and significant humoral immune impairment who are being evaluated for treatment with convalescent plasma. The European Conference of Infections in Leukemia (ECIL-9) as well as the National Comprehensive Cancer Network (NCCN) recommend consideration of convalescent plasma for hematologic/BMT patients who are SARS-CoV-2 seronegative [191] [192-194]. An additional use of serology is for prioritization of new monoclonal antibody therapies, if they become available in the future, especially if supplies are limited. Prioritizing treatment for those individuals most in need of protection could help optimize utilization of resources. Of note, a thorough review of convalescent plasma or monoclonal antibody therapies for COVID-19 is outside of the scope of this guideline.

Positive anti-SARS-CoV-2 antibody testing is part of the CDC case definition for MIS-C [195]. However, false positive results may detract from identifying the true cause of illness. For example, for children it is important to differentiate MIS-C from other inflammatory processes such as bacterial infections, Kawasaki Disease or rheumatic fever because the management and long term follow up of these entities is different.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

There are also potential harms to serologic testing after vaccination. False positive results may promote a false sense of security and lead individuals to take fewer steps to protect themselves against SARS-CoV-2 or to not seek treatment when it would otherwise have been indicated.

False negative results are also possible, which could cause emotional distress for previously vaccinated individuals by leading them to assume that the vaccine was ineffective. Post-vaccination antibody test results may be negative in individuals without a history of previous natural infection if the test used does not detect the type of antibodies induced by the vaccine.

Other considerations

While current EUA indications do not preclude the use of SARS-CoV2 antibody tests in vaccinated individuals, none of the currently authorized tests has been authorized to assess humoral immunity post-vaccination or to define a threshold of protection after infection. Therefore, the FDA recommends against SARS-CoV-2 antibody testing to assess immunity.

Detection of anti-RBD-bAbs has generally correlated with the emergence of nAbs and the detection of nAbs has been associated with protection against COVID-19. Vaccine clinical trial data also showed that higher antibody levels (either bAbs or nAbs) were associated with fewer breakthrough infections. Despite these observations, a definitive correlate of protection has not been identified. One complicating factor is that antibody levels measured across different studies used different antibody tests that had not been calibrated to a common reference standard such as the WHO international standard for anti-SARS-CoV-2 immunoglobulin [196]. Currently, only one commercial test has been authorized to detect nAbs from individuals with recent or prior SARS-CoV-2 infection [197]. While this assay has been calibrated against the WHO standard, it was not validated for testing post-vaccination or for predicting protection from re-infection. In addition, a given antibody

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

titer may provide lower protection against variants compared with the strains included in the vaccine or that caused prior infection. Furthermore, serologic testing does not assess the full spectrum of immune responses to infection or vaccination. Induction of T-cell immunity plays a critical role in protection against SARS-CoV-2, and while the potential importance of viral mutations and T-cell immune evasion is debated, it is unlikely that variants will be able to evade SARS-CoV-2-specific cell mediated immunity. Currently, assays designed to quantify T-cell immune function are not widely available for clinical use.

Conclusions and research needs for this recommendation

Higher antibody levels generally correlate with protection against SARS-CoV-2 infection, but a single titer that predicts protection has not yet been identified. Therefore, antibody testing (either with bAbs or nAbs) to assess for immunity to SARS-CoV-2 is not recommended routinely. Antibody testing should not be used to guide vaccination, re-vaccination or booster decisions.

More research is needed to determine the role of SARS-CoV-2 antibody testing in evaluating immunity against SARS-CoV-2 and to better understand if antibody tests will be helpful for identifying “non-responders” who should receive repeated COVID-19 vaccination or a different schedule for boosters. Efforts to better predict antibody longevity, correlation of bAb levels to nAbs levels, and serological surrogates of immune protection (including how this may differ in individuals who also have a history of both natural COVID-19 and vaccination) are needed. Future studies should use standardized assays that are- calibrated to an international standard.

Last updated X Date and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

Discussion

Early in the COVID-19 pandemic, there was intense interest in measuring antibody responses to SARS-CoV-2 infection, with the hope that a correlate of protective immunity would be identified. Similar interest accompanied release of results of clinical trials of the first SARS-CoV-2 vaccines. In response, intensive and wide-ranging research into the immunology of SARS-CoV-2 was conducted. This work yielded important insights, including that prior infection and vaccination reduce the risk of severe and fatal COVID-19, and that the presence of neutralizing antibodies (versus their absence) and higher binding antibody concentrations (versus lower concentrations) provide greater risk reduction. Yet despite these discoveries, and after almost 800 million infections and administration of 13.5 billion vaccine doses [5], the hope that a serologic marker of protection will be found remains unrealized. Consequently, current clinical indications for testing SARS-CoV-2 antibodies are few. In addition, as seroprevalence approaches 100% in most human populations, measuring antibodies has declined in importance as a public health strategy to surveil for SARS-CoV-2 infection.

In the current guideline, the IDSA panel identified only one clinical situation in which antibody testing is recommended: to assist with the diagnosis of MIS-C in children. Of note, ongoing assessment of the value of serologic testing in this clinical setting will be difficult since a positive test result is included in the case definition [3]. The panel also acknowledges that a negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy such as convalescent plasma, monoclonal antibodies, or to prioritize administration of monoclonal therapies when supplies are limited.

To optimize diagnostic test accuracy when considering serologic testing, IgG, IgG/IgM, or total antibody assays are suggested over an IgM assay, due to reduced sensitivity of IgM alone. Testing should not be done during the first two weeks of symptoms, since antibody production is often not detectable until week 3 or later; of note, few data are available after 8 weeks of symptoms, and the panel did not assess studies that reported results after this time. If serology is being done to assess for evidence of previous SARS-CoV-2 infection in someone who has been vaccinated with an mRNA (e.g., Moderna COVID-19 vaccine), protein subunit (e.g., Novavax COVID-19 vaccine), or viral vector vaccine (e.g., J&J/Janssen COVID-19 vaccine, which is no longer available for use in the U.S.), serologic assays that target the nucleocapsid protein are preferred over those that target the spike protein, since these vaccines elicit anti-spike antibodies.

It is important to emphasize that serologic test performance remains variable and sometimes the same manufacturer's assay performed quite differently across studies. Factors that may have contributed to heterogeneity across studies include differences in the patient population tested, the exact timing of testing relative to symptom onset and the use of different NAAT assays as the reference standard for comparison. Patients with mild symptoms, or those who are asymptomatic [198], may display weaker immune responses to SARS-CoV-2 compared to those with severe illness. Standardized reporting of disease severity was not included in most studies. The exact timing of testing was also not specified in all studies. Uncertainty around the timing of testing could have affected the time-stratified analyses. In addition, most studies did not include an international standard. Future assays should be calibrated against an international reference standard such as that developed by the WHO

[199]. While in the previous version of this guideline, the clinical performance of LF assays was more variable than ELISA or CIA tests, this difference was not observed in the current updated literature review. Finally, in a new subgroup analysis, we found no substantive differences in test characteristics (i.e., sensitivity and specificity) based on viral antigen (i.e, spike vs nucleocapsid protein).

Conclusions

Clinicians and public health officials need to understand the indications for serologic testing and the performance of serology assays used in their settings to accurately interpret anti-SARS-CoV-2 antibody test results. Whenever possible, serologic assays with established high sensitivity and specificity (i.e., $\geq 99.5\%$) should be employed. IgG, IgG/IgM and total antibody tests appear to have better sensitivity and specificity than other immunoglobulin classes and perform best when used between three to five weeks after symptom onset. The clinical indications for antibody testing to support a diagnosis of COVID-19 are limited. Antibodies to SARS-CoV-2 support the diagnosis of MIS-C in children. A negative spike antibody test may be a useful metric to identify immunocompromised patients who are candidates for immune therapy such as convalescent plasma, monoclonal antibodies, or to prioritize administration of monoclonal therapies when supplies are limited. The current high seroprevalence of anti-SARS-CoV-2 antibodies in most populations reduces the value of antibody testing for epidemiologic purposes. While higher antibody titers and presence of neutralizing antibodies correlate with reduced risk of SARS-CoV-2 infection, a correlate of immune protection from infection has not been defined.

Notes

Financial Support

This project was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 6 NU50CK000477-04-01). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this guideline do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.

COI Summary

The following list displays what has been reported to the IDSA. To provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process which includes assessment by the Board of Directors liaison to the Standards and Practice Guideline Committee and, if necessary, the Conflicts of Interest (COI) and Ethics Committee. The assessment of disclosed relationships for possible COI is based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. **M.H.** serves on a clinical adjudication panel for Sanofi; receives research funding from the Centers for Disease Control and Prevention (CDC) and CDC Foundation; serves on the *Society for Healthcare*

Commented [GD1]: We may also need to add Omar Al Ta'ani, Jamil Nazzal, Shahad Iqneibi COI info if they indicate a disclosure.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

1052 *Epidemiology of America (SHEA)* Board of Directors and Chair of the SHEA Education & Research
1053 Foundation; received other numerations from Sage, Medline, and Molnylycke; and served as
1054 Chair of the IDSA Diagnostics Committee. **K.H.** served an advisor to Quidel, BioFire, Pfizer, and
1055 Takeda; received other numerations from Quidel, Pfizer and Takeda; served Editor to American
1056 Society of Microbiology (ASM) and member of Clinical and Laboratory Standards Institute
1057 Antifungal Committee; received research funding from the National Institutes of Health (NIH);
1058 and served on the exam committee for the American Board of Internal Medicine, and associate
1059 editor for Open Forum Infectious Diseases. **J.E.** serves as a consultant for Sanofi Pasteur, Pfizer,
1060 and AstraZeneca; an advisor/consultant for Meissa Vaccines; receives research funding from the
1061 CDC, Pfizer, Brotman Baty Research Institute, Merck, Novavax, GlaxoSmithKline, and
1062 AstraZeneca; served as an advisor to Teva Pharmaceuticals; and served as member of Pediatric
1063 Infectious Diseases Society (PIDS) Publication Committee and Transplant ID Committee. **R.H.**
1064 [serves on the advisory board for Specific Diagnostics; serves as an advisor for](#)
1065 [ThermoFisher, Qiagen, Torus, and Roche; serves as an editor for the Journal of Clinical](#)
1066 [Microbiology \(JCM\); serves as a member for the College of American Pathology and the](#)
1067 [Clinical and Laboratory Standards Institute \(CLSI\); serves as Vice-chair for the Diagnostics](#)
1068 [Committee at the Infectious Diseases Society of America \(IDSA\); serves on the Professional](#)
1069 [Practices Group at the American Society for Microbiology \(ASM\); receives research funding](#)
1070 [from Qiagen, bioMerieux, Momentum Diagnostics, Specific Diagnostics, IHMA and Pattern;](#)
1071 [served as a consultant for bioMerieux.](#) **M.L.** serves as an advisor for Sanofi, Seqirus, Medicago,
1072 GSK, Janssen, Novavax, Pfizer, MD Brief; receives research funding from the Canadian Institutes
1073 of Health Research, World Health Organization (WHO), Medical Research Council (United

Commented [GD2]: @Dzanya, Loretta

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

1074 Kingdom), has received in-kind supply of vaccine from Sanofi, has been paid for expert
1075 testimony on institutional and workplace vaccine policy, and has served on the DSMB for
1076 CanSino Biologics and an advisor to Merck. **D.M.** serves as a member for the Society for
1077 Healthcare Epidemiology of America (SHEA); receives research funding from the Centers for
1078 Disease Control and Prevention (CDC), National Institute of Health (NIH), Veterans Affairs,
1079 Health Services Research and Development (HRSD) and the Agency for Healthcare Research and
1080 Quality (AHRQ). **R.P.** has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on
1081 a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on
1082 an anti-biofilm substance issued; serves as consultant to PhAST, Torus Biosystems, Day Zero
1083 Diagnostics, Mammoth Biosciences, Netflix, Abbott Laboratories, Oxford Nanopore
1084 Technologies, CARB-X, Qvella, and HealthTrackRx; receives other numeration from NBME,
1085 UpToDate, and the Infectious Disease Board Review Course; received grants from CD
1086 Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate, ContraFect, TenNor
1087 Therapeutics Limited, Shionogi, NIH, BIOFIRE, Adaptive Phage Therapeutics, National Science
1088 Foundation, and the Department of Defense; and has served as a consultant to Curetis, Specific
1089 Technologies, NextGen Diagnostics, Pathoquest, Selux Diagnostics, and 1928 Diagnostics. **S.S.**
1090 serves as a Board member for the Evidence Foundation, receives honoraria for evidence
1091 reviews, methodological support and teaching from the Evidence Foundation; serves on
1092 guideline panels for the American Gastroenterological Association (AGA); and receives research
1093 funding from the Department of Veterans Affairs Evidence Synthesis Program. **Y.F.Y.** serves as a
1094 Board member for the Evidence Foundation; receives honoraria for evidence reviews,
1095 methodological support and teaching from the Evidence Foundation, the AGA for evidence

Commented [GD3]: @Dzanya, Loretta

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

1096 reviews, and the Institute for Clinical and Economic Review (ICER) for committee meetings;
1097 serves as a Director for the Evidence Foundation and for the U.S. GRADE Network; and served
1098 on an Independent Appraisal Committee for ICER. **R.M** serves as a Board member for the
1099 Evidence Foundation; and receives honoraria for evidence reviews, methodological support and
1100 teaching from the Evidence Foundation. **M.H.M** serves as a Board member for the Evidence
1101 Foundation; receives honoraria for evidence reviews, methodological support and teaching
1102 from the Evidence Foundation; receives research funding from the Agency for Healthcare
1103 Research and Quality, the Endocrine Society, and the Society for Vascular Surgery; has received
1104 research funding the American Society of Hematology and the WHO; and has served as a
1105 guideline methodologist for the WHO. **A.B.** received honorarium from the ICER. **R.A.M** serves
1106 as a Board member for the Evidence Foundation; receives honoraria for evidence reviews,
1107 methodological support and teaching from the Evidence Foundation, and ICER for committee
1108 meetings; receives research funding from the NIH, the WHO, the American College of
1109 Rheumatology, the American Society of Hematology, and Bohringer Ingelheim; serves as Chair
1110 of the Midwest Comparative Effectiveness Public Advisory Council of the ICER; serves on the
1111 Methods Committee for Kidney Disease Improving Global Outcomes Work Group; serves on the
1112 Clinical Guidelines Committee for the Canadian Society of Nephrology; and previously served on
1113 the Clinical Guidelines Committee for the American College of Physicians (ACP). All authors have
1114 submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the
1115 editors consider relevant to the content of the manuscript have been disclosed. All other
1116 authors report no potential conflicts.

References

1. Centers for Disease Control and Prevention. Nationwide COVID-19 Infection and Vaccination Induced Antibody Seroprevalence (Blood donations). Available at: <https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022> Accessed 01 August 2023
2. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS Med* **2022**; 19(11): e1004107.
3. Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available at: <https://www.cdc.gov/mis/mis-c/hcp/index.html>. Accessed 1 January 2023 and 20 August 2023
4. Dinc HO, Saltoglu N, Can G, et al. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. *Vaccine* **2022**; 40(1): 52-8.
5. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: <https://covid19.who.int/#:~:text=Globally%2C%20as%20of%201%3A56pm,vaccine%20doses%20have%20been%20administered>. Accessed 03 August 2023 and 27 August 2023
6. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science Immunology* **2020**; 5(48): eabc8413.
7. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veasler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**; 181(2): 281-92.e6.
8. Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. *Nature Communications* **2020**; 11(1): 2806.
9. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. *Trends Immunol* **2020**; 41(5): 355-9.
10. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. *Journal of Virology* **2020**; 94(13): e00647-20.
11. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. *Nature Reviews Immunology* **2006**; 6(3): 231-43.
12. Lee CY-P, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. *Front Immunol* **2020**; 11: 879-.
13. Administration USFD. Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19). Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transition-plan-medical-devices-issued-emergency-use-authorizations-euas-related-coronavirus-disease>. Accessed 20 August 2023
14. Hanson KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. *Clin Infect Dis* **2020**.
15. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* **2011**; 64(4): 395-400.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1156 16. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a
1157 generalized linear mixed model approach. *J Clin Epidemiol* **2006**; 59(12): 1331-2; author reply 2-
1158 3.
- 1159 17. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality
1160 assessment of diagnostic accuracy studies. *Ann Intern Med* **2011**; 155(8): 529-36.
- 1161 18. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-
1162 randomised studies of interventions. *BMJ* **2016**; 355: i4919.
- 1163 19. Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 1. Study design, risk of
1164 bias, and indirectness in rating the certainty across a body of evidence for test accuracy. *J Clin*
1165 *Epidemiol* **2020**; 122: 129-41.
- 1166 20. Schünemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 2. Test accuracy:
1167 inconsistency, imprecision, publication bias, and other domains for rating the certainty of
1168 evidence and presenting it in evidence profiles and summary of findings tables. *J Clin Epidemiol*
1169 **2020**; 122: 142-52.
- 1170 21. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015
1171 (developed by Evidence Prime, Inc.). Available at: <https://gradeprorg.org/>.
- 1172 22. Narasimhan M, Mahimainathan L, Araj E, et al. Clinical evaluation of the abbott alinity sars-cov-2
1173 spike-specific quantitative igg and igm assays among infected, recovered, and vaccinated
1174 groups. *Journal of Clinical Microbiology* **2021**; 59(7).
- 1175 23. Hibino M, Watanabe S, Tobe S, et al. Antibody responses to SARS-CoV-2 nucleocapsid and spike
1176 proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional
1177 study in Japan. *Respir Investig* **2022**; 60(2): 256-63.
- 1178 24. Maine GNL, K. M.: Krishnan, S. M.: Afolayan-Oloye, O.: Fatemi, S.: Kumar, S.: VanHorn, L.:
1179 Hurand, A.: Sykes, E.: Sun, Q. Longitudinal characterization of the IgM and IgG humoral response
1180 in symptomatic COVID-19 patients using the Abbott Architect. *J Clin Virol* **2020**; 133: 104663.
- 1181 25. Cs L, Sp H, YI L, Sk P, Tc A. Performance of an automated chemiluminescent immunoassay for
1182 SARS-COV-2 IgM and head-to-head comparison of Abbott and Roche COVID-19 antibody assays.
1183 *Practical Laboratory Medicine* **2021**; 25.
- 1184 26. Interiano CM, S.: Turner, B.: Gonzalez, M.: Rogers, B.: Jerris, R.: Weinzierl, E.: Elkhaila, M.:
1185 Leung-Pineda, V. Longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG
1186 assays in a pediatric population. *Practical Laboratory Medicine* **2021**; 25.
- 1187 27. Higgins VF, A.: Wang, X. Y.: Bhandari, M.: Daghfal, D. J.: Kulasingam, V. Anti-SARS-CoV-2 IgM
1188 improves clinical sensitivity early in disease course. *Clin Biochem* **2021**; 90: 1-7.
- 1189 28. Conklin SEM, K.: Manabe, Y. C.: Schmidt, H. A.: Miller, J.: Keruly, M.: Klock, E.: Kirby, C. S.: Baker,
1190 O. R.: Fernandez, R. E.: Eby, Y. J.: Hardick, J.: Shaw-Saliba, K.: Rothman, R. E.: Caturegli, P. P.:
1191 Redd, A. D.: Tobian, A. A. R.: Bloch, E. M.: Larman, H. B.: Quinn, T. C.: Clarke, W.: Laeyendecker,
1192 O. Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing. *J*
1193 *Clin Microbiol* **2021**; 59(2).
- 1194 29. Fujigaki HT, M.: Osawa, M.: Sakurai, A.: Nakamoto, K.: Seto, K.: Fujita, T.: Hata, T.: Akiyama, H.:
1195 Doi, Y.: Saito, K. Reliability of serological tests for COVID-19: comparison of three
1196 immunochromatography test kits for SARS-CoV-2 antibodies. *Heliyon* **2020**; 6(9): e04929.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1197 30. Pérez-García FP-T, R.: Romanyk, J.: Arroyo, T.: Gómez-Herruz, P.: Cuadros-González, J. Alltest
1198 rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days
1199 after symptom onset: A prospective single-center study. *J Clin Virol* **2020**; 129: 104473.
- 1200 31. Serrano MMR, D. N.: Palop, N. T.: Arenas, R. O.: Córdoba, M. M.: Mochón, M. D. O.: Cardona, C.
1201 G. Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody
1202 detection. *J Clin Virol* **2020**; 129: 104529.
- 1203 32. Jung JG, E.: Jariwala, P.: Pham, H.: Huang, R.: Benzi, E.: Issaq, N.: Matzuk, M.: Singh, I.: Devaraj, S.
1204 Clinical performance of a semi-quantitative assay for SARS-CoV2 IgG and SARS-CoV2 IgM
1205 antibodies. *Clin Chim Acta* **2020**; 510: 790-5.
- 1206 33. Imai KT, S.: Ikeda, M.: Noguchi, S.: Kitagawa, Y.: Matuoka, M.: Miyoshi, K.: Tarumoto, N.: Sakai,
1207 J.: Ito, T.: Maesaki, S.: Tamura, K.: Maeda, T. Clinical evaluation of an immunochromatographic
1208 IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. *J Clin*
1209 *Virol* **2020**; 128: 104393.
- 1210 34. Qiu XX, Y.: Sun, J.: Wang, X.: Chen, G.: Xu, X.: Liao, S.: Yang, N.: Li, S.: Yang, G.: Tang, Y.: Fan, J.:
1211 Xie, W.: Hu, H.: Li, Y.: Zheng, F. Dynamic changes of throat swabs RNA and serum antibodies for
1212 SARS-CoV-2 and their diagnostic performances in patients with COVID-19. *Emerg Microbes*
1213 *Infect* **2020**; 9(1): 1974-83.
- 1214 35. Lin YC, Lee YL, Cheng CY, et al. Multicenter evaluation of four immunoassays for the
1215 performance of early diagnosis of COVID-19 and assessment of antibody responses of patients
1216 with pneumonia in Taiwan. *J Microbiol Immunol Infect* **2021**; 54(5): 816-29.
- 1217 36. Stein DRO, C.: Gretchen, A.: Thorlacius, L.: Fudge, D.: Lang, A.: Sekirov, I.: Morshed, M.: Levett, P.
1218 N.: Tran, V.: Kus, J. V.: Gubbay, J.: Mohan, V.: Charlton, C.: Kanji, J. N.: Tipples, G.: Serhir, B.:
1219 Therrien, C.: Roger, M.: Jiao, L.: Zahariadis, G.: Needle, R.: Gilbert, L.: Desnoyers, G.: Garceau, R.:
1220 Bouhtiauy, I.: Longtin, J.: El-Gabalawy, N.: Dibernardo, A.: Lindsay, L. R.: Drebot, M. Evaluation of
1221 commercial SARS-CoV-2 serological assays in Canadian public health laboratories. *Diagnostic*
1222 *Microbiology and Infectious Disease* **2021**; 101(3).
- 1223 37. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal
1224 Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. *J Appl Lab Med* **2020**;
1225 5(5): 908-20.
- 1226 38. Egger MB, C.: Wiesinger, K.: Gabriel, C.: Clodi, M.: Mueller, T.: Dieplinger, B. Comparison of the
1227 Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for
1228 the detection of SARS-CoV-2 antibodies in human plasma. *Clin Chim Acta* **2020**; 509: 18-21.
- 1229 39. Bundschuh CE, M.: Wiesinger, K.: Gabriel, C.: Clodi, M.: Mueller, T.: Dieplinger, B. Evaluation of
1230 the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG
1231 antibodies in human plasma. *Clin Chim Acta* **2020**; 509: 79-82.
- 1232 40. Velay AG, F.: Benotmane, I.: Wendling, M. J.: Danion, F.: Collange, O.: De Sèze, J.: Schmidt-
1233 Mutter, C.: Schneider, F.: Bilbault, P.: Meziani, F.: Fafi-Kremer, S. Evaluation of the performance
1234 of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. *Diagn*
1235 *Microbiol Infect Dis* **2020**; 98(4): 115181.
- 1236 41. Whitman JDH, J.: Mowery, C. T.: Shy, B. R.: Yu, R.: Yamamoto, T. N.: Rathore, U.: Goldgof, G. M.:
1237 Whitty, C.: Woo, J. M.: Gallman, A. E.: Miller, T. E.: Levine, A. G.: Nguyen, D. N.: Bapat, S. P.:
1238 Balcerek, J.: Bylsma, S. A.: Lyons, A. M.: Li, S.: Wong, A. W.: Gillis-Buck, E. M.: Steinhart, Z. B.:
1239 Lee, Y.: Apathy, R.: Lipke, M. J.: Smith, J. A.: Zheng, T.: Boothby, I. C.: Isaza, E.: Chan, J.: Acenas,

- 1240 D. D., 2nd; Lee, J.; Macrae, T. A.; Kyaw, T. S.; Wu, D.; Ng, D. L.; Gu, W.; York, V. A.; Eskandarian,
1241 H. A.; Callaway, P. C.; Warrior, L.; Moreno, M. E.; Levan, J.; Torres, L.; Farrington, L. A.;
1242 Loudermilk, R. P.; Koshal, K.; Zorn, K. C.; Garcia-Beltran, W. F.; Yang, D.; Astudillo, M. G.;
1243 Bernstein, B. E.; Gelfand, J. A.; Ryan, E. T.; Charles, R. C.; Iafrate, A. J.; Lennerz, J. K.; Miller, S.;
1244 Chiu, C. Y.; Stramer, S. L.; Wilson, M. R.; Manglik, A.; Ye, C. J.; Krogan, N. J.; Anderson, M. S.;
1245 Cyster, J. G.; Ernst, J. D.; Wu, A. H. B.; Lynch, K. L.; Bern, C.; Hsu, P. D.; Marson, A. Evaluation of
1246 SARS-CoV-2 serology assays reveals a range of test performance. *Nat Biotechnol* **2020**; 38(10):
1247 1174-83.
- 1248 42. Nilles EJ, Karlson EW, Norman M, et al. Evaluation of Three Commercial and Two Non-
1249 Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2. *J Appl Lab Med*
1250 **2021**; 6(6): 1561-70 %8 Nov 1 %! Evaluation of Three Commercial and Two Non-Commercial
1251 Immunoassays for the Detection of Prior Infection to SARS-CoV-2 %@ 2576-9456 (Print) 2475-
1252 7241.
- 1253 43. Kulkarni R, Shrivastava S, Patil H, et al. Performance assessment of SARS-CoV-2 IgM & IgG ELISAs
1254 in comparison with plaque reduction neutralization test. *Indian Journal of Medical Research*
1255 **2021**; 153(5): 658-64.
- 1256 44. Boum Y, Fai KN, Nikolay B, et al. Performance and operational feasibility of antigen and antibody
1257 rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a
1258 clinical, prospective, diagnostic accuracy study. *The Lancet Infectious Diseases* **2021**; 21(8):
1259 1089-96.
- 1260 45. Fischer PU, Fischer K, Curtis KC, et al. Evaluation of commercial rapid lateral flow tests, alone or
1261 in combination, for SARS-CoV-2 antibody testing. *American Journal of Tropical Medicine and*
1262 *Hygiene* **2021**; 105(2): 378-86.
- 1263 46. Saluzzo FM, P.; Poletti De Chaurand, V.; Quaresima, V.; Cugnata, F.; Di Serio, C.; Macé, A.; De
1264 Vos, M.; Sacks, J. A.; Cirillo, D. M. SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological
1265 Tools in Challenging Settings. *Microbiol Spectr* **2021**; e0025021.
- 1266 47. Gebrecherkos T, Kiros YK, Challa F, et al. Longitudinal profile of antibody response to SARS-CoV-
1267 2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal
1268 study. *PLoS One* **2022**; 17(3): e0263627.
- 1269 48. Pegoraro MM, V.; Salvagno, G. L.; Gaino, S.; Bassi, A.; Caloi, C.; Peretti, A.; Bizzego, S.; Poletto, L.;
1270 Bovo, C.; Lippi, G.; Lo Cascio, G. Evaluation of three immunochromatographic tests in COVID-19
1271 serologic diagnosis and their clinical usefulness. *European Journal of Clinical Microbiology and*
1272 *Infectious Diseases* **2021**; 40(4): 897-900.
- 1273 49. Soleimani RK, M.; Gruson, D.; Rodriguez-Villalobos, H.; Berghmans, M.; Belkhir, L.; Yombi, J. C.;
1274 Kabamba-Mukadi, B. Clinical usefulness of fully automated chemiluminescent immunoassay for
1275 quantitative antibody measurements in COVID-19 patients. *J Med Virol* **2021**; 93(3): 1465-77.
- 1276 50. Montesinos IG, D.; Kabamba, B.; Dahma, H.; Van den Wijngaert, S.; Reza, S.; Carbone, V.;
1277 Vandenberg, O.; Gulbis, B.; Wolff, F.; Rodriguez-Villalobos, H. Evaluation of two automated and
1278 three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. *J Clin*
1279 *Virol* **2020**; 128: 104413.
- 1280 51. Ou JT, M.; He, H.; Tan, H.; Mai, J.; Long, Y.; Jiang, X.; He, Q.; Huang, Y.; Li, Y.; Chen, R.; Li, L.; Shi,
1281 Y.; Li, F. SARS-CoV-2 Antibodies and Associated Factors at Different Hospitalization Time Points
1282 in 192 COVID-19 Cases. *The journal of applied laboratory medicine* **2021**.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1283 52. Al Haddad C, Finianos P, Germanos M, Feghali R, Hasan H. Comparison of four automated SARS-
1284 CoV-2 serological immunoassays in Lebanon. *Ann Biol Clin (Paris)* **2021**; 79(6): 579-86.
- 1285 53. Wakita MI, M.: Saito, K.: Horiuchi, Y.: Yamatani, K.: Ishikawa, S.: Yamamoto, T.: Igawa, G.: Hinata,
1286 M.: Kadota, K.: Kurosawa, T.: Takahashi, S.: Saito, T.: Misawa, S.: Akazawa, C.: Naito, T.: Miida, T.:
1287 Takahashi, K.: Ai, T.: Tabe, Y. Comparison of the clinical performance and usefulness of five
1288 SARS-CoV-2 antibody tests. *PLoS ONE* **2021**; 16(2 February).
- 1289 54. Tré-Hardy MW, A.: Beukinga, I.: Favresse, J.: Dogné, J. M.: Douxfils, J.: Blairon, L. Analytical and
1290 clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. *J Med Virol*
1291 **2021**; 93(2): 803-11.
- 1292 55. Jacot DM, M.: Coste, A. T.: Aubry, C.: Sacks, J. A.: Greub, G.: Croxatto, A. Evaluation of sixteen
1293 ELISA SARS-CoV-2 serological tests. *Journal of Clinical Virology* **2021**; 142.
- 1294 56. Pecoraro VC, T.: Meacci, M.: Gargiulo, R.: Capobianchi, M. R.: Mussini, C.: Vecchi, E.: Pecorari,
1295 M.: Gagliotti, C.: Trenti, T.: Sarti, M. Accuracy of the serological detection of IgG and IgM to
1296 SARS-Cov-2: a prospective, cross-sectional study. *European Journal of Clinical Microbiology and*
1297 *Infectious Diseases* **2021**; 40(9): 1891-8.
- 1298 57. Yamamoto M, Okazaki K, Kitai Y, et al. Comparison of six antibody assays and two combination
1299 assays for COVID-19. *Virol J* **2022**; 19(1): 24.
- 1300 58. Mairesse AF, J.: Eucher, C.: Elsen, M.: Tré-Hardy, M.: Haventith, C.: Gruson, D.: Dogné, J. M.:
1301 Douxfils, J.: Göbbels, P. High clinical performance and quantitative assessment of antibody
1302 kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies.
1303 *Clin Biochem* **2020**; 86: 23-7.
- 1304 59. Nakano YK, M.: Morita, Y.: Shimura, T.: Yokoyama, R.: Qian, C.: Xia, F.: He, F.: Kishi, Y.: Okada, J.:
1305 Yoshikawa, N.: Nagura, Y.: Okazaki, H.: Moriya, K.: Seto, Y.: Kodama, T.: Yatomi, Y. Time course
1306 of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic
1307 COVID-19 in Japan. *Scientific reports* **2021**; 11(1): 2776.
- 1308 60. Guedez-López GVA-G, M.: González-Donapetry, P.: Bloise, I.: Tornero-Marin, C.: González-García,
1309 J.: Mingorance, J.: García-Rodríguez, J.: Montero-Vega, M. D.: Romero, M. P.: García-Bujalance,
1310 S.: Cendejas-Bueno, E.: Ruiz-Carrascoso, G.: Lázaro-Perona, F.: Falces-Romero, I.: Gutiérrez-
1311 Arroyo, A.: Girón de Velasco-Sada, P.: Rico Nieto, A.: Loeches, B.: Ruiz-Bastián, M.: Gómez-
1312 Arroyo, B.: García-Clemente, P.: Liras-Hernández, M. G.: García-Sánchez, C.: Sánchez-Castellano,
1313 M.: San José-Villar, S.: Tato, E.: Romero Huertas, C.: Molina Muñoz, E. Evaluation of three
1314 immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2. *European*
1315 *Journal of Clinical Microbiology and Infectious Diseases* **2020**; 39(12): 2289-97.
- 1316 61. Chansaenroj JY, R.: Posuwan, N.: Puenpa, J.: Sudhinaraset, N.: Chirathaworn, C.: Poovorawan, Y.
1317 Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19
1318 patients. *Virol J* **2021**; 18(1): 52.
- 1319 62. Choi HW, Jeon CH, Won EJ, Kang SJ, Lee SY, Kee SJ. Performance of Severe Acute Respiratory
1320 Syndrome Coronavirus 2 Serological Diagnostic Tests and Antibody Kinetics in Coronavirus
1321 Disease 2019 Patients. *Front Microbiol* **2022**; 13: 881038.
- 1322 63. Buntinx FC, P.: Gulikers, M.: Verbakel, J.: Jan, L.: Van der Elst, M.: Van Elslande, J.: Van Ranst, M.:
1323 Vermeersch, P. Added value of anti-SARS-CoV-2 antibody testing in a Flemish nursing home
1324 during an acute COVID-19 outbreak in April 2020. *Acta Clin Belg* **2020**: 1-6.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1325 64. Wolff FD, H.: Duterte, C.: Van den Wijngaert, S.: Vandenberg, O.: Cotton, F.: Montesinos, I.
1326 Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4
1327 automated immunoassays. *Diagn Microbiol Infect Dis* **2020**; 98(3): 115140.
- 1328 65. Wolf JK, T.: Pehnke, S.: Nickel, O.: Lübbert, C.: Kalbitz, S.: Arnold, B.: Ermisch, J.: Berger, L.:
1329 Schroth, S.: Isermann, B.: Borte, S.: Biemann, R. Differences of SARS-CoV-2 serological test
1330 performance between hospitalized and outpatient COVID-19 cases. *Clinica Chimica Acta* **2020**;
1331 511: 352-9.
- 1332 66. Zervou FN, Louie P, Stachel A, et al. SARS-CoV-2 antibodies: IgA correlates with severity of
1333 disease in early COVID-19 infection. *Journal of Medical Virology* **2021**; 93(9): 5409-15.
- 1334 67. Bal AP, B.: Traubad, M. A.: Escuret, V.: Rabilloud, M.: Langlois-Jacques, C.: Paul, A.: Guibert, N.:
1335 D'Aubardère-Frieh, C.: Massardier-Pilonchery, A.: Fabien, N.: Goncalves, D.: Boibieux, A.: Morfin-
1336 Sherpa, F.: Pitiot, V.: Gueyffier, F.: Lina, B.: Fassier, J. B.: Trouillet-Assant, S. Evaluation of High-
1337 Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-
1338 19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test. *Clinical*
1339 *chemistry* **2021**; 67(5): 742-52.
- 1340 68. Traugott MA, S. W.: Aberle, J. H.: Griebler, H.: Karolyi, M.: Pawelka, E.: Puchhammer-Stöckl, E.:
1341 Zoufaly, A.: Weseslindtner, L. Performance of Severe Acute Respiratory Syndrome Coronavirus 2
1342 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked
1343 Immunosorbent Assays and Rapid Tests. *J Infect Dis* **2020**; 222(3): 362-6.
- 1344 69. Nicholson SK, T.: Khvorov, A.: Douros, C.: Mordant, F.: Bond, K.: Druce, J.: Williamson, D. A.:
1345 Purcell, D.: Lewin, S. R.: Sullivan, S.: Subbarao, K.: Catton, M. Evaluation of 6 Commercial SARS-
1346 CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.
1347 *Open Forum Infectious Diseases* **2021**; 8(7).
- 1348 70. Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection since exposure and
1349 post symptom onset. *Eur Respir J* **2020**; 56(2): 2000763.
- 1350 71. Liu Z-L, Liu Y, Wan L-G, et al. Antibody profiles in mild and severe cases of COVID-19. *Clin Chem*
1351 **2020**.
- 1352 72. Butterfield TRB-M, A.: Phillips, Y. Z. R.: Brown, N.: Francis, K.: Brown, J.: Walker, J. P.: McKnight,
1353 N. A. L.: Eikhmetalar, K.: Taylor, D. K.: Bruce, C. A.: McGrowder, D.: Wharfe, G.: Sandiford, S.
1354 L.: Thompson, T. K.: Anzinger, J. J. Assessment of commercial SARS-CoV-2 antibody assays,
1355 Jamaica. *International Journal of Infectious Diseases* **2021**; 105: 333-6.
- 1356 73. Dellièvre SS, M.: Minier, M.: Gabassi, A.: Alanio, A.: Le Goff, J.: Delaunier, C.: Chaix, M. L.
1357 Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech. *J Clin Microbiol* **2020**;
1358 58(8).
- 1359 74. Dortet LE, C.: Vauloup-Fellous, C.: Khechare, M.: Ronat, J. B.: Fortineau, N.: Roque-Afonso, A.
1360 M.: Naas, T. Rapid Determination of SARS-CoV-2 antibodies using a bedside, point-of-Care,
1361 serological test. *Emerg Microbes Infect* **2020**; 9(1): 2212-21.
- 1362 75. Ali AH, Zidan AS. Detection of Antibodies in Patients with COVID-19 by Rapid Chromatographic
1363 Immunoassay. *Turkish Journal of Immunology* **2022**; 10(2): 115-20.
- 1364 76. Serre-Miranda CN, C.: Roque, S.: Canto-Gomes, J.: Silva, C. S.: Vieira, N.: Barreira-Silva, P.: Alves-
1365 Peixoto, P.: Cotter, J.: Reis, A.: Formigo, M.: Sarmento, H.: Pires, O.: Carvalho, A.: Petrovsky, D.
1366 Y.: Diéguez, L.: Sousa, J. C.: Sousa, N.: Capela, C.: Palha, J. A.: Cunha, P. G.: Correia-Neves, M.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1367 Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised
1368 COVID-19 patients. *International Journal of Infectious Diseases* **2021**; 104: 661-9.
- 1369 77. Infantino MG, V.: Lari, B.: Bambi, R.: Perri, A.: Manneschi, M.: Terenzi, G.: Liotti, I.: Ciotta, G.:
1370 Taddei, C.: Benucci, M.: Casprini, P.: Veneziani, F.: Fabbri, S.: Pompetti, A.: Manfredi, M.
1371 Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM
1372 and IgG antibodies: an Italian experience. *J Med Virol* **2020**; 92(9): 1671-5.
- 1373 78. Turbett SEA, M.: Dighe, A. S.: Garcia Beltran, W.: Miller, T.: Scott, H.: Durbin, S. M.: Bharadwaj,
1374 M.: Thomas, J.: Gogakos, T. S.: Astudillo, M.: Lennerz, J.: Rosenberg, E. S.: Branda, J. A.
1375 Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-
1376 Test Algorithms. *J Clin Microbiol* **2020**; 59(1).
- 1377 79. Harley KG, I. L. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott
1378 Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays. *J Clin Microbiol* **2020**; 59(1).
- 1379 80. Paiva KJG, R. D.: Chan, P. A.: Huard, R. C.: Callendo, A. M.: Lonks, J. R.: King, E.: Tang, E. W.: Pytel-
1380 Parenteau, D. L.: Nam, G. H.: Yakirevich, E.: Lu, S. Validation and performance comparison of
1381 three SARS-CoV-2 antibody assays. *J Med Virol* **2021**; 93(2): 916-23.
- 1382 81. Tang MSH, K. G.: Logsdon, N. M.: Hayes, J. E.: Gronowski, A. M.: Anderson, N. W.: Farnsworth, C.
1383 W. Clinical Performance of Two SARS-CoV-2 Serologic Assays. *Clin Chem* **2020**; 66(8): 1055-62.
- 1384 82. Chew KLT, S. S.: Saw, S.: Pajarillaga, A.: Zaine, S.: Khoo, C.: Wang, W.: Tambyah, P.: Jureen, R.:
1385 Sethi, S. K. Clinical evaluation of serological IgG antibody response on the Abbott Architect for
1386 established SARS-CoV-2 infection. *Clin Microbiol Infect* **2020**; 26(9): 1256.e9-e11.
- 1387 83. Tan SSS, S.: Chew, K. L.: Huak, C. Y.: Khoo, C.: Pajarillaga, A.: Wang, W.: Tambyah, P.: Ong, L.:
1388 Jureen, R.: Sethi, S. K. Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2
1389 serological assays. *Pathology* **2020**; 52(7): 770-7.
- 1390 84. Theel ESH, J.: Hilgart, H.: Granger, D. Performance Characteristics of Four High-Throughput
1391 Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. *J Clin Microbiol* **2020**; 58(8).
- 1392 85. Aoki KT, K.: Nagasawa, T.: Kashiwagi, K.: Mori, N.: Matsubayashi, K.: Satake, M.: Tanaka, I.:
1393 Kodama, N.: Shimodaira, T.: Ishii, Y.: Miyazaki, T.: Ishii, T.: Morita, T.: Yoshimura, T.: Tateda, K.
1394 Combination of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Diagnosis. *Ann Lab*
1395 *Med* **2021**; 41(6): 568-76.
- 1396 86. Wehrhahn MCB, S. J.: Newcombe, J. P.: Chong, S.: Evans, J.: Figtree, M.: Hainke, L.: Hueston, L.:
1397 Khan, S.: Marland, E.: O'Sullivan, M. V. N.: Powell, H.: Roy, J.: Waring, L.: Yu, M.: Robson, J. An
1398 evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a
1399 predominantly mildly symptomatic low prevalence Australian population. *Journal of Clinical*
1400 *Virology* **2021**; 138.
- 1401 87. Hubbard JAG, K. A.: Khan, J.: Szczepiorkowski, Z. M.: de Gijzel, D.: Ovalle, A. A.: AlSalman, A. S.:
1402 Gallagher, T. L.: Johnston, A. A.: Tibbetts, A. R.: Vital, S. E.: Cervinski, M. A.: Nerenz, R. D.
1403 Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid
1404 Antibodies. *The journal of applied laboratory medicine* **2021**; 6(2): 429-40.
- 1405 88. Therrien CS, B.: Bélanger-Collard, M.: Skrzypczak, J.: Shank, D. K.: Renaud, C.: Girouard, J.:
1406 Loungnarath, V.: Carrier, M.: Brochu, G.: Tourangeau, F.: Gilfix, B.: Piche, A.: Bazin, R.: Guérin, R.:
1407 Lavoie, M.: Martel-Laferrrière, V.: Fortin, C.: Benoit, A.: Marcoux, D.: Gauthier, N.: Laumaea, A.
1408 M.: Gasser, R.: Finzi, A.: Roger, M. Multicenter evaluation of the clinical performance and the

- 1409 neutralizing antibody activity prediction properties of 10 high-throughput serological assays
1410 used in clinical laboratories. *Journal of Clinical Microbiology* **2021**; 59(3).
- 1411 89. Bond KAW, E.: Nicholson, S.: Lim, S.: Johnson, D.: Cox, B.: Putland, M.: Gardiner, E.: Tippet, E.:
1412 Graham, M.: Mordant, F.: Catton, M.: Lewin, S. R.: Subbarao, K.: Howden, B. P.: Williamson, D. A.
1413 Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody
1414 detection. *Pathology* **2021**; 53(6): 773-9.
- 1415 90. Maine GN, Krishnan SM, Walewski K, Trueman J, Sykes E, Sun Q. Clinical and analytical
1416 evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two
1417 other serological tests. *J Immunol Methods* **2022**; 503: 113243.
- 1418 91. Chen SYL, Y. L.: Lin, Y. C.: Lee, N. Y.: Liao, C. H.: Hung, Y. P.: Lu, M. C.: Wu, J. L.: Tseng, W. P.: Lin,
1419 C. H.: Chung, M. Y.: Kang, C. M.: Lee, Y. F.: Lee, T. F.: Cheng, C. Y.: Chen, C. P.: Huang, C. H.: Liu, C.
1420 E.: Cheng, S. H.: Ko, W. C.: Hsueh, P. R.: Chen, S. C. Multicenter evaluation of two
1421 chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and
1422 assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. *Emerg Microbes Infect*
1423 **2020**; 9(1): 2157-68.
- 1424 92. Plaga AW, R.: Olson, E.: Payto, D.: Harrington, J.: Nwe-Kissig, P. T.: Strizzi, M.: Zilka, S.: Ko, J.:
1425 Colón-Franco, J. M. Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-
1426 2 for Use in Clinical Laboratories. *The journal of applied laboratory medicine* **2021**; 6(4): 998-
1427 1004.
- 1428 93. Catry EJ, H.: Dodemont, M.: Saad Albichr, I.: Lardinois, B.: de fays, B.: Delaere, B.: Closset, M.:
1429 Laurent, T.: Denis, O.: Galanti, L.: Mullier, F.: Huang, T. D. Analytical and clinical evaluation of
1430 four commercial SARS-CoV-2 serological immunoassays in hospitalized patients and ambulatory
1431 individuals. *Journal of Virological Methods* **2021**; 289.
- 1432 94. Harrington DA, T.: Rosmarin, C.: Cutino-Moguel, T.: Hopkins, M. Evaluation of 2 commercial anti-
1433 SARS-CoV-2 antibody assays in an immunocompetent and immunocompromised inpatient
1434 population with COVID-19. *Diagn Microbiol Infect Dis* **2021**; 101(2): 115449.
- 1435 95. Yun SR, J. H.: Jang, J. H.: Bae, H.: Yoo, S. H.: Choi, A. R.: Jo, S. J.: Lim, J.: Lee, J.: Ryu, H.: Cho, S. Y.:
1436 Lee, D. G.: Lee, J.: Kim, S. C.: Park, Y. J.: Lee, H.: Oh, E. J. Comparison of SARS-CoV-2 Antibody
1437 Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
1438 *Annals of laboratory medicine* **2021**; 41(6): 577-87.
- 1439 96. Yang JP, E. C.: Hamilton, C.: Neibauer, T.: Robyak, K.: McGhee, P.: Speicher, T.: Zhu, Y. Analytical
1440 and Clinical Analysis of Two Automated Anti-SARS-CoV-2 Immunoassays in Pre-Pandemic and
1441 Pandemic Patient Populations. *The journal of applied laboratory medicine* **2021**; 6(2): 441-50.
- 1442 97. Bryan AP, G.: Wener, M. H.: Fink, S. L.: Morishima, C.: Chaudhary, A.: Jerome, K. R.: Mathias, P.
1443 C.: Greninger, A. L. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay
1444 and Seroprevalence in Boise, Idaho. *J Clin Microbiol* **2020**; 58(8).
- 1445 98. Lokida D, Karyana M, Kosasih H, et al. Performance and correlation of ten commercial
1446 immunoassays for the detection of SARS-CoV-2 antibodies. *Heliyon* **2022**; 8(12): e12614.
- 1447 99. Escribano PÁ-U, A.: Alonso, R.: Catalán, P.: Alcalá, L.: Muñoz, P.: Guinea, J. Detection of SARS-
1448 CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19. *Sci Rep* **2020**;
1449 10(1): 19893.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1450 100. Kohmer NW, S.: Rühl, C.: Ciesek, S.: Rabenau, H. F. Brief clinical evaluation of six high-
1451 throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol* **2020**; 129: 104480.
- 1452 101. Kubota KK, Y.: Matsuoka, M.: Imai, K.: Orihara, Y.: Kawamura, R.: Sakai, J.: Ishibashi, N.:
1453 Tarumoto, N.: Takeuchi, S.: Maesaki, S.: Maeda, T. Clinical evaluation of the antibody response
1454 in patients with COVID-19 using automated high-throughput immunoassays. *Diagnostic*
1455 *Microbiology and Infectious Disease* **2021**; 100(3).
- 1456 102. Jugwanth S, Gedezha MP, Mampeule N, et al. Performance of the Abbott SARS-CoV-2 IgG
1457 serological assay in South African 2 patients. *PLoS ONE* **2022**; 17(2): e0262442.
- 1458 103. Merrill AEJ, J. B.: Ehlers, A.: Voss, D.: Krasowski, M. D. Head-to-Head Comparison of Two SARS-
1459 CoV-2 Serology Assays. *J Appl Lab Med* **2020**; 5(6): 1351-7.
- 1460 104. Huyghe EJ, H.: Matheeußen, V.: Hoffbauer, I.: Goossens, H.: Peeters, B. Performance of three
1461 automated SARS-CoV-2 antibody assays and relevance of orthogonal testing algorithms. *Clin*
1462 *Chem Lab Med* **2020**; 59(2): 411-9.
- 1463 105. Kittel MM, M. C.: Zahn, I.: Roth, H. J.: Thiaucourt, M.: Gerhards, C.: Haselmann, V.: Neumaier,
1464 M.: Findeisen, P. Clinical evaluation of commercial automated SARS-CoV-2 immunoassays. *Int J*
1465 *Infect Dis* **2021**; 103: 590-6.
- 1466 106. Nilsson ACH, D. K.: Justesen, U. S.: Gorm-Jensen, T.: Andersen, N. S.: Øvrehus, A.: Johansen, I. S.:
1467 Michelsen, J.: Sprogø, U.: Lillevang, S. T. Comparison of six commercially available SARS-CoV-2
1468 antibody assays-Choice of assay depends on intended use. *Int J Infect Dis* **2021**; 103: 381-8.
- 1469 107. Caturegli GM, J.: Howard, B. M.: Caturegli, P. Clinical Validity of Serum Antibodies to SARS-CoV-2
1470 : A Case-Control Study. *Ann Intern Med* **2020**; 173(8): 614-22.
- 1471 108. Cota GF, M. L.: de Souza, C. S.: Pedras, M. J.: Saliba, J. W.: Faria, V.: Alves, L. L.: Rabello, A.:
1472 Avelar, D. M. Diagnostic performance of commercially available COVID-19 serology tests in
1473 Brazil. *International Journal of Infectious Diseases* **2020**; 101: 382-90.
- 1474 109. Buchholtz MLA, F. M.: Eichhorn, P.: Weigand, M.: Kleinhempel, A.: Häusler, K.: Bruegel, M.:
1475 Holdt, L. M.: Teupser, D. SARS-CoV-2 antibody immunoassays in serial samples reveal earlier
1476 seroconversion in acutely ill COVID-19 patients developing ARDS. *PLoS ONE* **2021**; 16(5 May).
- 1477 110. Favresse JC, J.: Eucher, C.: Elsen, M.: Laffineur, K.: Dogné, J. M.: Douxfils, J. Clinical performance
1478 of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike
1479 proteins. *Journal of Medical Virology* **2021**; 93(4): 2262-9.
- 1480 111. Van Elslande JH, E.: Depypere, M.: Brackenier, A.: Desmet, S.: André, E.: Van Ranst, M.: Lagrou,
1481 K.: Vermeersch, P. Diagnostic performance of seven rapid IgG/IgM antibody tests and the
1482 Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect* **2020**; 26(8): 1082-7.
- 1483 112. Huber TS, P.: Irrgang, P.: Korn, K.: Tenbusch, M.: Diesch, K.: Achenbach, S.: Kremer, A. E.:
1484 Werblow, M.: Vetter, M.: Bogdan, C.: Held, J. Diagnostic performance of four SARS-CoV-2
1485 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral
1486 respiratory infections. *European Journal of Clinical Microbiology and Infectious Diseases* **2021**.
- 1487 113. Hörber SS, J.: Relker, L.: Jürgens, S.: Guthier, J.: Peter, S.: Lehmann, R.: Peter, A. Evaluation of
1488 three fully-automated SARS-CoV-2 antibody assays. *Clinical Chemistry and Laboratory Medicine*
1489 **2020**; 58(12): 2113-20.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1490 114. Sarina Yang H, Racine-Brzostek SE, Lee WT, et al. SARS-CoV-2 antibody characterization in
1491 emergency department, hospitalized and convalescent patients by two semi-quantitative
1492 immunoassays. Clin Chim Acta **2020**.
- 1493 115. Yassine HMA-J, H.: Al-Sadeq, D. W.: Dargham, S. R.: Younes, S. N.: Shurrah, F.: Marei, R. M.:
1494 Hssain, A. A.: Taleb, S.: Alhussain, H.: Al-Nesf, M. A.: Al-Khal, A.: Qotba, H.: Althani, A. A.: Tang,
1495 P.: Abu-Raddad, L. J.: Nasrallah, G. K. Performance evaluation of five ELISA kits for detecting
1496 anti-SARS-COV-2 IgG antibodies. International Journal of Infectious Diseases **2021**; 102: 181-7.
- 1497 116. Florin LM, K.: Vandewal, W.: Bernard, D.: Robbrecht, J. Performance Evaluation of the Siemens
1498 SARS-CoV-2 Total Antibody and IgG Antibody Test. Laboratory medicine **2021**.
- 1499 117. Igawa G, Yamamoto T, Baba Y, et al. Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody
1500 assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area. Heliyon **2021**;
1501 7(11): e08393 %7 20211116 %8 Nov %! Clinical Evaluation of Siemens SARS-CoV-2 Total
1502 Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area %@
1503 2405-8440 (Print) 2405-8440.
- 1504 118. Tan SSS, S.: Chew, K. L.: Wang, C.: Pajarillaga, A.: Khoo, C.: Wang, W.: Ali, Z. M.: Yang, Z.: Chan, Y.
1505 H.: Tambyah, P.: Jureen, R.: Sethi, S. K. Comparative Clinical Evaluation of the Roche Elecsys and
1506 Abbott Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serology Assays for
1507 Coronavirus Disease 2019 (COVID-19). Arch Pathol Lab Med **2021**; 145(1): 32-8.
- 1508 119. Charpentier CI, H.: Damond, F.: Bouvet, E.: Chaix, M. L.: Ferré, V.: Delaugerre, C.: Mahjoub, N.:
1509 Larrouy, L.: Le Hingrat, Q.: Visseaux, B.: Mackiewicz, V.: Descamps, D.: Fidouh-Houhou, N.
1510 Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and
1511 one IgG automated immunoassay (Abbott). J Clin Virol **2020**; 132: 104618.
- 1512 120. Marlet JP, C.: Ragot, E.: Abou El Fattah, Y.: Guillon, A.: Marchand Adam, S.: Lemaigen, A.:
1513 Bernard, L.: Desoubreaux, G.: Blasco, H.: Barin, F.: Stefic, K.: Gaudy-Graffin, C. Clinical
1514 performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective
1515 analysis for the diagnosis of COVID-19 in a real-life routine care setting. J Clin Virol **2020**; 132:
1516 104633.
- 1517 121. Tanis JV, E.: Piérard, D.: Weets, I.: Bjerke, M.: Schiettecatte, J.: De Geyter, D. Evaluation of four
1518 laboratory-based SARS-CoV-2 IgG antibody immunoassays. Diagnostic Microbiology and
1519 Infectious Disease **2021**; 100(1).
- 1520 122. Vauloup-Fellous CM, S.: Périllaud-Dubois, C.: Brichler, S.: Alloui, C.: Gordien, E.: Rameix-Welti, M.
1521 A.: Gault, E.: Moreau, F.: Fourati, S.: Challine, D.: Pawlotsky, J. M.: Houhou-Fidouh, N.: Damond,
1522 F.: Mackiewicz, V.: Charpentier, C.: Méritet, J. F.: Rozenberg, F.: Podglajen, I.: Marot, S.: Petit, H.:
1523 Burrel, S.: Akhavan, S.: Leruez-Ville, M.: Avettand-Fenoel, V.: Fourgeaud, J.: Guillemot, T.:
1524 Gardiennet, E.: Bonacorsi, S.: Carol, A.: Carcelain, G.: Villemonteix, J.: Boukli, N.: Gozlan, J.:
1525 Morand-Joubert, L.: Legoff, J.: Delaugerre, C.: Chaix, M. L.: Roque-Afonso, A. M.: Dortet, L.: Naas,
1526 T.: Ronat, J. B.: Lepape, S.: Marcelin, A. G.: Descamps, D. Performance of 30 commercial SARS-
1527 CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis
1528 **2021**; 40(10): 2235-41.
- 1529 123. Prazuck TC, M.: Giachè, S.: Gubavu, C.: Seve, A.: Rzepecki, V.: Chevereau-Choquet, M.: Kiani, C.:
1530 Rodot, V.: Lionnet, E.: Courtellemont, L.: Guinard, J.: Pialoux, G.: Hocqueloux, L. Evaluation of
1531 performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole
1532 blood samples from the fingertip. PLoS One **2020**; 15(9): e0237694.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1533 124. Sisay AT, A.: Desale, A.: Ataro, I.: Woldeesenbet, Z.: Nigusse, B.: Tayachew, A.: Kebede, A.: Desta,
1534 A. F. Diagnostic Performance of SARS-CoV-2 IgM/IgG Rapid Test Kits for the Detection of the
1535 Novel Coronavirus in Ethiopia. *J Multidiscip Healthc* **2021**; 14: 171-80.
- 1536 125. Puschel KF, C.: Peñaloza, B.: Abarca, K.: Rojas, M. P.: Tellez, A.: Moore, P.: Cea, A. M.: Wilson, C.:
1537 Cid, V.: Montero, J. Clinical and serological profile of asymptomatic and non-severe symptomatic
1538 COVID-19 cases: Lessons from a longitudinal study in primary care in Latin America. *BJGP Open*
1539 **2021**; 5(1): 1-8.
- 1540 126. Ong DSYdM, S. J.: Lindeboom, F. A.: Koeleman, J. G. M. Comparison of diagnostic accuracies of
1541 rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus
1542 disease 2019 presenting to the hospital. *Clin Microbiol Infect* **2020**; 26(8): 1094.e7-.e10.
- 1543 127. Shen B, Zheng Y, Zhang X, et al. Clinical evaluation of a rapid colloidal gold
1544 immunochromatography assay for SARS-Cov-2 IgM/IgG. *Am J Transl Res* **2020**; 12(4): 1348-54.
- 1545 128. Rostamzadeh DM, S.: Alinejad, M.: Jooya, S. R.: Eskandarian, M.: Metvaei, A.: Vafaei, S.:
1546 Aboulghasemi, H.: Younesi, V.: Shabani, M. Serological assay for anti-SARS-CoV-2 antibodies
1547 improves sensitivity of diagnosis of COVID-19 patients. *Medical Microbiology and Immunology*
1548 **2021**.
- 1549 129. Kim JK, Ryu SW, Kim JS, Jung BK. Performance evaluation of four rapid antibody tests for the
1550 detection of severe acute respiratory syndrome coronavirus 2. *Journal of Clinical Laboratory*
1551 *Analysis* **2022**.
- 1552 130. Ozturk AB, T.: Simsek Bozok, T. Evaluation of rapid antibody test and chest computed
1553 tomography results of COVID-19 patients: A retrospective study. *Journal of Medical Virology*
1554 **2021**.
- 1555 131. Pérez-García FP-T, R.: Iglesias, M. E.: Romanyk, J.: Arroyo, T.: Gómez-Herruz, P.: González, R.:
1556 Lapeña García, S.: Cuadros-González, J. Comparative evaluation of six immunoassays for the
1557 detection of antibodies against SARS-CoV-2. *Journal of Virological Methods* **2021**; 289.
- 1558 132. Pallett SJCD, S. J.: Patel, A.: Charani, E.: Mughal, N.: Stebbing, J.: Davies, G. W.: Moore, L. S. P.
1559 Point-of-care SARS-CoV-2 serological assays for enhanced case finding in a UK inpatient
1560 population. *Sci Rep* **2021**; 11(1): 5860.
- 1561 133. Baron RCR, L.: Weber, M.: Thiel, S.: Grossmann, K.: Wohlwend, N.: Lung, T.: Hillmann, D.: Ritzler,
1562 M.: Bigler, S.: Egli, K.: Ferrara, F.: Bodmer, T.: Imperiali, M.: Heer, S.: Renz, H.: Flatz, L.: Kohler, P.:
1563 Vernazza, P.: Kahlert, C. R.: Paprotny, M.: Risch, M. Frequency of serological non-responders and
1564 false-negative RT-PCR results in SARS-CoV-2 testing: A population-based study. *Clinical*
1565 *Chemistry and Laboratory Medicine* **2020**; 58(12): 2131-40.
- 1566 134. Chamkhi S, Dhaouadi T, Sfar I, et al. Comparative study of six SARS-CoV-2 serology assays:
1567 Diagnostic performance and antibody dynamics in a cohort of hospitalized patients for
1568 moderate to critical COVID-19. *Int J Immunopathol Pharmacol* **2022**; 36: 20587384211073232.
- 1569 135. Charpentier CP, G.: Ichou, H.: Ferré, V. M.: Larfi, I.: Phung, B. C.: Vallois, D.: LeGac, S.: Aubier, M.:
1570 Descamps, D.: Fidouh-Houhou, N.: Bouvet, E. Contribution of rapid lateral flow assays from
1571 capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a
1572 pilot study in a university hospital, Paris, France. *Diagn Microbiol Infect Dis* **2021**; 101(2):
1573 115430.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1574 136. Chen JN, Z.: Li, H.: Tang, D.: Zhang, P. Analysis of Nucleic Acid and Antibody Detection Results for
1575 SARS-CoV-2 Infection. Arch Iran Med **2021**; 24(5): 427-33.
- 1576 137. Cross GB, Naftalin CM, Ngiam JN, et al. Discrepant serological findings in SARS-CoV-2 PCR-
1577 negative hospitalized patients with fever and acute respiratory symptoms during the pandemic.
1578 Journal of Medical Virology **2022**.
- 1579 138. de Almeida SMS, R. N.: Nogueira, M. B.: Sanada, B.: Cavalli, B. M.: Rotta, I.: Takahashi, G. R. A.:
1580 Pereira, L. A.: Moreira, F. B.: Dino, C. L. T.: Graf, M. E.: de Almeida, B. M. M.: Domino, N. R.:
1581 Genelhou, G.: Bochnia-Bueno, L.: Raboni, S. M. Rapid Serological Tests for SARS-CoV-2:
1582 Diagnostic Performance of 4 Commercial Assays. Med Princ Pract **2021**; 30(4): 385-94.
- 1583 139. Mirijello AZ, M.: Miscio, G.: de Matthaeis, A.: Piscitelli, P.: Carbonelli, C. M.: Di Giorgio, A.:
1584 Inglese, M.: Ciliberti, G. L.: Marciano, C.: Borelli, C.: Vergara, D.: Castorani, G.: Orciulo, G. V.: Di
1585 Mauro, L.: Carella, M.: Simeone, A.: Copetti, M.: Leone, M. A.: De Cosmo, S. Diagnosis of covid-
1586 19 in patients with negative nasopharyngeal swabs: Reliability of radiological and clinical
1587 diagnosis and accuracy versus serology. Diagnostics **2021**; 11(3).
- 1588 140. Nakagama YK, Y.: Candray, K.: Nakagama, S.: Sano, F.: Tsuchida, T.: Kunishima, H.: Imai, T.:
1589 Shintani, A.: Nitahara, Y.: Kaku, N.: Kido, Y. Serological Testing Reveals the Hidden COVID-19
1590 Burden among Health Care Workers Experiencing a SARS-CoV-2 Nosocomial Outbreak. Microbiol
1591 Spectr **2021**: e0108221.
- 1592 141. Pan Y, Li X, Yang G, et al. Serological immunochromatographic approach in diagnosis with SARS-
1593 CoV-2 infected COVID-19 patients. J Infect **2020**; 81(1): e28-e32.
- 1594 142. Reich N, Lowe CF, Puddicombe D, et al. Repeat virological and serological profiles in hospitalized
1595 patients initially tested by nasopharyngeal RT-PCR for SARS-CoV-2. J Med Virol **2021**; 93(12):
1596 6808-12.
- 1597 143. Rostamzadeh D, Mortezaagholi S, Alinejad M, et al. Serological assay for anti-SARS-CoV-2
1598 antibodies improves sensitivity of diagnosis of COVID-19 patients. Med Microbiol Immunol **2021**;
1599 210(5-6): 283-9.
- 1600 144. Sacristan MSC-B, A.: Cintas, M. I. Z.: García, A. S.: de Villavicencio, C. Y.: Maestre, M. M.
1601 Comparison of various serological assays for novel SARS-COV-2. Eur J Clin Microbiol Infect Dis
1602 **2021**; 40(5): 963-8.
- 1603 145. Tawiah KDH, K. G.: Farnsworth, C. W. Limited Diagnostic Utility of SARS-CoV-2 Serologic Testing
1604 in Symptomatic PCR Negative Patients. J Appl Lab Med **2021**; 6(4): 1083-5.
- 1605 146. Van Praet JTC, A. S.: Van De Moortele, K.: Descheemaeker, P.: Reynders, M. Comparison of four
1606 commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT
1607 findings. Infection **2021**; 49(1): 145-8.
- 1608 147. Yokoyama RK, M.: Morita, Y.: Shimura, T.: Nakano, Y.: Qian, C.: Xia, F.: He, F.: Kishi, Y.: Okada, J.:
1609 Yoshikawa, N.: Nagura, Y.: Okazaki, H.: Moriya, K.: Seto, Y.: Kodama, T.: Yatomi, Y. Validation of a
1610 new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system
1611 detecting both N and S proteins in Japan. PLoS One **2021**; 16(3): e0247711.
- 1612 148. Zhao JY, Q.: Wang, H.: Liu, W.: Liao, X.: Su, Y.: Wang, X.: Yuan, J.: Li, T.: Li, J.: Qian, S.: Hong, C.:
1613 Wang, F.: Liu, Y.: Wang, Z.: He, Q.: Li, Z.: He, B.: Zhang, T.: Fu, Y.: Ge, S.: Liu, L.: Zhang, J.: Xia, N.:
1614 Zhang, Z. Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019.
1615 Clinical Infectious Diseases **2020**; 71(16): 2027-34.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1616 149. Belhadjer Z, Méot M, Bajolle F, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome
1617 in Children in the Context of Global SARS-CoV-2 Pandemic. *Circulation* **2020**; 142(5): 429-36.
- 1618 150. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New
1619 York State. *New England Journal of Medicine* **2020**; 383(4): 347-58.
- 1620 151. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children
1621 and Adolescents. *New England Journal of Medicine* **2020**; 383(4): 334-46.
- 1622 152. Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging
1623 disease following SARS-CoV-2 infection in critically ill children. *Annals of Intensive Care* **2020**;
1624 10(1): 69.
- 1625 153. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory
1626 shock in children during COVID-19 pandemic. *The Lancet* **2020**; 395(10237): 1607-8.
- 1627 154. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in
1628 children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*
1629 **2020**; 369: m2094.
- 1630 155. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian
1631 epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *The Lancet* **2020**;
1632 395(10239): 1771-8.
- 1633 156. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric
1634 Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *JAMA* **2020**;
1635 324(3): 259-69.
- 1636 157. Mamishi SE, G. G.: Mohammadi, M.: Abdolsalehi, M. R.: Sadeghi, R. H.: Mahmoudi, S.:
1637 Pourakbari, B. Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral
1638 hospital-based study. *Human Antibodies* **2021**; 29(3): 217-23.
- 1639 158. Sweeney NM, B.: Pedro Galão, R.: Pickering, S.: Botgros, A.: Wilson, H. D.: Signell, A. W.:
1640 Betancor, G.: Tan, M. K. I.: Ramble, J.: Kouphou, N.: Acors, S.: Graham, C.: Seow, J.: MacMahon,
1641 E.: Neil, S. J. D.: Malim, M. H.: Doores, K.: Douthwaite, S.: Batra, R.: Nebbia, G.: Edgeworth, J. D.
1642 Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of
1643 suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service
1644 implemented during the first pandemic wave. *PLoS One* **2021**; 16(4): e0249791.
- 1645 159. Centers for Disease Control and Prevention. Information for Healthcare Providers about
1646 Multisystem Inflammatory Syndrome in Children (MIS-C). Case Definition for MIS-C Available at:
1647 [https://www.cdc.gov/mis/mis-](https://www.cdc.gov/mis/mis-c/hcp_cstecdc/index.html#:~:text=Case%20Definition%20for%20MIS%2DC&text=Any%20illness%20in%20a%20person,The%20vital%20records%20criteria%20(Suspect))
1648 [c/hcp_cstecdc/index.html#:~:text=Case%20Definition%20for%20MIS%2DC&text=Any%20illness](https://www.cdc.gov/mis/mis-c/hcp_cstecdc/index.html#:~:text=Case%20Definition%20for%20MIS%2DC&text=Any%20illness%20in%20a%20person,The%20vital%20records%20criteria%20(Suspect))
1649 [%20in%20a%20person,The%20vital%20records%20criteria%20\(Suspect\)](https://www.cdc.gov/mis/mis-c/hcp_cstecdc/index.html#:~:text=Case%20Definition%20for%20MIS%2DC&text=Any%20illness%20in%20a%20person,The%20vital%20records%20criteria%20(Suspect)) Accessed 8 August
1650 2023.
- 1651 160. Centers for Disease Control and Prevention. Nationwide Commercial Lab Pediatric Antibody
1652 Seroprevalence. Available at: [https://covid.cdc.gov/covid-data-tracker/#pediatric-](https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence)
1653 [seroprevalence](https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence). Accessed 10 May 2023.
- 1654 161. McCrindle BW, Harahsheh AS, Handoko R, et al. SARS-CoV-2 Variants and Multisystem
1655 Inflammatory Syndrome in Children. *N Engl J Med* **2023**; 388(17): 1624-6.
- 1656 162. Jain E, Donowitz JR, Aarons E, Marshall BC, Miller MP. Multisystem Inflammatory Syndrome in
1657 Children after SARS-CoV-2 Vaccination. *Emerg Infect Dis* **2022**; 28(5): 990-3.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1658 163. Mallon PWGT, W.: Leon, A. G.: McCann, K.: Kenny, G.: McGettrick, P.: Green, S.: Inzitari, R.:
1659 Cottare, A. G.: Feeney, E. R.: Savinelli, S.: Doran, P. Dynamic Change and Clinical Relevance of
1660 Postinfectious SARS-CoV-2 Antibody Responses. *Open Forum Infect Dis* **2021**; 8(8): ofab122.
- 1661 164. Charlton CLK, J. N.: Johal, K.: Bailey, A.: Plitt, S. S.: MacDonald, C.: Kunst, A.: Buss, E.: Burnes, L.
1662 E.: Fonseca, K.: Berenger, B. M.: Schnabl, K.: Hu, J.: Stokes, W.: Zelyas, N.: Tipples, G. Evaluation
1663 of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for
1664 Detection of SARS-CoV-2 Antibodies. *J Clin Microbiol* **2020**; 58(10).
- 1665 165. Choe JYK, J. W.: Kwon, H. H.: Hong, H. L.: Jung, C. Y.: Jeon, C. H.: Park, E. J.: Kim, S. K. Diagnostic
1666 performance of immunochromatography assay for rapid detection of IgM and IgG in coronavirus
1667 disease 2019. *J Med Virol* **2020**; 92(11): 2567-72.
- 1668 166. Meng QBP, J. J.: Wei, X.: Yang, J. Y.: Li, P. C.: Qu, Z. W.: Xiong, Y. F.: Wu, G. J.: Hu, Z. M.: Yu, J. C.:
1669 Su, W. Clinical application of combined detection of SARS-CoV-2-specific antibody and nucleic
1670 acid. *World J Clin Cases* **2020**; 8(19): 4360-9.
- 1671 167. Manalac JY, J.: Calayag, K.: Nguyen, L.: Patel, P. M.: Zhou, D.: Shi, R. Z. Evaluation of Abbott anti-
1672 SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. *Clin Chim Acta* **2020**;
1673 510: 687-90.
- 1674 168. Martinaud CH, C.: Iger, A.: Bigaillon, C.: Bonnet, C.: Mérens, A.: Wolf, A.: Foissaud, V.: Lepar-
1675 Goffart, I. Evaluation of the Quotient® MosaiQ™ COVID-19 antibody microarray for the
1676 detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans. *J Clin Virol* **2020**; 130:
1677 104571.
- 1678 169. Cobb BL, Lloyd M, Hock KG, Farnsworth CW. Clinical Performance of a Lateral Flow SARS-CoV-2
1679 Total Antibody Assay. *J Appl Lab Med* **2022**; 7(4): 827-33.
- 1680 170. Van Elslande J, Oyaert M, Lorent N, et al. Lower persistence of anti-nucleocapsid compared to
1681 anti-spike antibodies up to one year after SARS-CoV-2 infection. *Diagn Microbiol Infect Dis* **2022**;
1682 103(1): 115659.
- 1683 171. Grossberg AN, Koza LA, Ledreux A, et al. A multiplex chemiluminescent immunoassay for
1684 serological profiling of COVID-19-positive symptomatic and asymptomatic patients. *Nature*
1685 *Communications* **2021**; 12(1).
- 1686 172. Şener B, Kirbaş E, Sancak B, et al. PERFORMANCE EVALUATION OF SIX DIFFERENT SARS-CoV-2
1687 ANTIBODY IMMUNOASSAYS: DISEASE SEVERITY AND SERUM SAMPLING TIME AFFECT THE
1688 SENSITIVITY. *Jpn J Infect Dis* **2022**.
- 1689 173. Bolotin S, Tran V, Osman S, et al. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by
1690 Anti-Nucleocapsid Antibody Decline. *J Infect Dis* **2021**; 223(8): 1334-8.
- 1691 174. Softeland JM, Gisslen M, Liljeqvist JA, et al. Longevity of anti-spike and anti-nucleocapsid
1692 antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent
1693 controls. *Am J Transplant* **2022**; 22(4): 1245-52.
- 1694 175. Addetia AC, K. H. D.: Dingens, A.: Zhu, H.: Roychoudhury, P.: Huang, M. L.: Jerome, K. R.: Bloom,
1695 J. D.: Greninger, A. L. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in
1696 Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol* **2020**; 58(11).
- 1697 176. Ali AMA, K. M.: Fatah, M. H.: Tawfeeq, H. M.: Rostam, H. M. SARS-CoV-2 reinfection in patients
1698 negative for immunoglobulin G following recovery from COVID-19. *New Microbes New Infect*
1699 **2021**; 43: 100926.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1700 177. Atti A, Insalata F, Carr EJ, et al. Antibody correlates of protection from SARS-CoV-2 reinfection
1701 prior to vaccination: A nested case-control within the SIREN study. (1532-2742 (Electronic)).
- 1702 178. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection
1703 against symptomatic reinfection. *Journal of Infection* **2021**; 82(4): e29-e30.
- 1704 179. Hønge BL, Hindhede L, Kaspersen KA, et al. Long-term detection of SARS-CoV-2 antibodies after
1705 infection and risk of re-infection. *Int J Infect Dis* **2022**; 116: 289-92.
- 1706 180. Lumley SFOD, D.: Stoesser, N. E.: Matthews, P. C.: Howarth, A.: Hatch, S. B.: Marsden, B. D.: Cox,
1707 S.: James, T.: Warren, F.: Peck, L. J.: Ritter, T. G.: de Toledo, Z.: Warren, L.: Axten, D.: Cornall, R.
1708 J.: Jones, E. Y.: Stuart, D. I.: Sreaton, G.: Ebner, D.: Hoosdally, S.: Chand, M.: Crook, D. W.:
1709 O'Donnell, A. M.: Conlon, C. P.: Pouwels, K. B.: Walker, A. S.: Peto, T. E. A.: Hopkins, S.: Walker, T.
1710 M.: Jeffery, K.: Eyre, D. W. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care
1711 Workers. *N Engl J Med* **2021**; 384(6): 533-40.
- 1712 181. Asderakis A, Khalid U, Koimtzis G, et al. An Analysis of Serological Response and Infection
1713 Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2)
1714 SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants. *Transplantation* **2022**; 106(7):
1715 1421-9.
- 1716 182. Anand S, Montez-Rath ME, Han J, et al. SARS-CoV-2 Vaccine Antibody Response and
1717 Breakthrough Infection in Patients Receiving Dialysis. *Annals of Internal Medicine* **2022**; 175(3):
1718 371-8.
- 1719 183. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection
1720 against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe*
1721 **2022**; 3(1): e52-e61.
- 1722 184. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
1723 COVID-19 vaccine efficacy clinical trial. *Science* **2022**; 375(6576): 43-50.
- 1724 185. McGee C, Shi M, House J, et al. Longitudinal Serological Surveillance for COVID-19 Antibodies
1725 after Infection and Vaccination. *Microbiology Spectrum* **2022**; 10(5).
- 1726 186. Murt A, Altıparmak MR, Yadigar S, et al. Antibody responses to the SARS-CoV-2 vaccines in
1727 hemodialysis patients: Is inactivated vaccine effective? *Ther Apher Dial* **2022**; 26(4): 769-74.
- 1728 187. Ollila TA, Masel RH, Reagan JL, et al. Seroconversion and outcomes after initial and booster
1729 COVID-19 vaccination in adults with hematologic malignancies. *Cancer* **2022**.
- 1730 188. Patnaik AP, Rout NK, Ahmed S, Dash KA, Praharaj AK, Patro ARK. Correlation of Breakthrough
1731 Infection During the Omicron Wave With Seropositivity of Vaccinated Patients Undergoing
1732 Hemodialysis. *Cureus* **2022**; 14(9): e29296.
- 1733 189. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health
1734 Care Workers. *N Engl J Med* **2021**; 385(16): 1474-84.
- 1735 190. Aldridge RW, Yavlinsky A, Nguyen V, et al. SARS-CoV-2 antibodies and breakthrough infections in
1736 the Virus Watch cohort. *Nat Commun* **2022**; 13(1): 4869.
- 1737 191. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of
1738 Immunocompromised Patients: A Systematic Review and Meta-analysis. *JAMA Netw Open* **2023**;
1739 6(1): e2250647.

Last updated February 9, 2024, and posted online at www.idsociety.org/COVID19guidelines/serology.
Please check website for most updated version of these guidelines.

- 1740 192. Bloch EM, Focosi D, Shoham S, et al. Guidance on the Use of Convalescent Plasma to Treat
1741 Immunocompromised Patients With Coronavirus Disease 2019. Clin Infect Dis **2023**; 76(11):
1742 2018-24.
- 1743 193. Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines From the Association for the
1744 Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern
1745 Med **2022**; 175(9): 1310-21.
- 1746 194. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in
1747 patients with haematological malignancies or haematopoietic cell transplantation, from the
1748 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia **2022**; 36(6): 1467-80.
- 1749 195. Centers for Disease Control and Prevention. About MIS. Available at:
1750 <https://www.cdc.gov/mis/about.html>. Accessed 10 May 2023.
- 1751 196. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-SARS-CoV-2
1752 immunoglobulin. Lancet **2021**; 397(10282): 1347-8.
- 1753 197. U.S. Food and Drug Administration. cPass SARS-CoV-2 Neutralization Antibody Detection Kit.
1754 Available at: <https://www.fda.gov/media/143583/download>. . Accessed 28 April 2023.
- 1755 198. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-
1756 CoV-2 infections. Nature Medicine **2020**.
- 1757 199. World Health Organization. WHO/BS.2020.2403 Establishment of the WHO International
1758 Standard and Reference Panel for anti-SARS-CoV-2 antibody. Available at:
1759 <https://www.who.int/publications/m/item/WHO-BS-2020.2403>. Accessed 27 August 2023.
- 1760
- 1761
- 1762